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Kurzfassung 
 
Leberfibrose ist die Folge einer chronischen hepatischen Schädigung und resultiert aus einer 
vermehrten Ablagerung von narbigem Bindegewebe durch aktivierte hepatische Sternzellen 
(HSZs). Während der Zelltod von Hepatozyten, den Parenchymzellen der Leber, eine 
kausale Rolle bei der Leberfibrosierung spielt, verstärkt der Zelltod von aktivierten HSZs die 
Rückbildung der Leberfibrose und der daraus resultierenden Komplikationen, welche für die 
hohe Sterberate dieser Krankheit verantwortlich sind. 
In der vorliegenden Arbeit konnte zum ersten Mal gezeigt werden, dass die 
Endocannabinoide Virodhamin, Noladin Ether und N-Arachidonoyl Dopamin (NADA) zu 
spezifischem Zelltod von HSZs führen. Hepatozyten sind durch starke Abwehrmechanismen 
wie Antioxidanzien und durch eine hohe Expression des Abbauenzyms von NADA resistent 
gegenüber NADA-induziertem Zelltod. Das Synthese-Enzym von NADA wird in Hepatozyten, 
jedoch nicht in HSZs, exprimiert. NADA stellt somit eine potentielle antifibrotische Substanz 
dar, die für therapeutische Zwecke genutzt werden kann. 
Des Weiteren wurde in früheren Studien eine starke Hochregulation des Endocannabinoids 
2-Arachidonoyl Glycerol (2-AG) in der geschädigten Leber beobachtet, während in dem 
ungeschädigten Organ nur niedrige 2-AG Level gemessen wurden. In dieser Arbeit konnte 
gezeigt werden, dass Nichtparenchymzellen der Leber den zellulären Ursprung von 2-AG 
darstellen. Die erhöhten 2-AG Level während hepatischer Schädigung kommen zum einen 
durch erhöhte Expression des Synthese-Enzyms und zum anderen durch die Herabsetzung  
der Degradations-Enzym-Level zustande. 
Aus früheren Studien ist bekannt, dass 2-AG zu apoptotischem Zelltod in HSZs, jedoch nicht 
in Hepatozyten, führt. HSZs und Hepatozyten weisen einen signifikanten Unterschied in der 
Expression von COX-2 auf, was eine unterschiedliche Metabolisierung des 
Endocannabinoids 2-AG bedingt. Die Produktion von PGD2-GE durch COX-2 in HSZs trägt 
möglicherweise zur disparaten Empfindlichkeit von Hepatozyten und HSCs gegenüber 2-AG-
induzierter Apoptose bei. 
Schlussendlich sollen die neuen Erkenntnisse über die Rolle Endocannabinoid-vermittelter 
Signalwege bei Leberschädigung ermöglichen, spezifische Komponenten dieses Systems zu 
beeinflussen um dadurch hepatische Fibrogenese zu reduzieren. 
 
 
 
 
 
 
Abstract 
Liver fibrosis is the response to chronic hepatic injury and results from an increased 
deposition of connective scar tissue by activated hepatic stellate cells (HSCs). Removal of 
activated HSCs preceded amelioration of fibrosis and can prevent further severe 
complications of chronic hepatic injury, which result in a high mortality rate worldwide. 
In this thesis it was shown the first time, that the endocannabinoids virodhamine, noladin 
ether and N-arachidonoyl dopamine (NADA) specifically induce cell death in HSCs but not in 
hepatocytes. Due to the selective expression of effective defence systems like antioxidants 
and the NADA degradation enzyme fatty acid amide hydrolase (FAAH), hepatocytes showed 
resistance to NADA-induced cell death. The synthesising enzyme of NADA was shown to be 
strongly expressed in hepatocytes but not in HSCs. Thus, NADA has therapeutic potential as 
an antifibrotic endogenous agent. 
Moreover, in a recent study it was shown that the endocannabinoid 2-arachidonoyl glycerol 
(2-AG) is strongly upregulated in the injured liver. In this thesis it is shown that elevated 2-AG 
levels during liver fibrogenesis are due to elevated expression of the 2-AG synthesising 
enzyme and decreased levels of the 2-AG degradation enzyme. The data further points to 
non-parenchymal cells rather than to hepatocytes being the most important cells in 2-AG 
metabolism in the liver.  
Recently it was shown that 2-AG specifically induces cell death in HScs but not in 
hepatocytes. HSCs and hepatocytes differentially express COX-2, leading to differential 
metabolism of 2-AG. The generation of pro-apoptotic PGD2-GE by COX-2 in HSCs possibly 
contributes to the different susceptibility of hepatocytes and HSCs towards 2-AG-induced cell 
death. 
In conclusion, the understanding of the role of endocannabinoid-mediated pathways in liver 
injury and fibrosis will make it possible to specifically target components of this system to 
decrease fibrogenesis. 
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Introduction   1 
1 INTRODUCTION 
  
During the last decade, the endocannabinoid system (ECS) has emerged as a key regulator 
of the pathogenesis of chronic liver diseases. This thesis focuses on the role of the ECS, 
including their ligands, receptors and the enzymes, which are involved in the synthesis and 
degradation of endocannabinoids, in hepatic fibrosis. To provide an insight into the topic, the 
introduction starts with a section about the pathology of this disease. Consecutively, the 
second section presents the hepatic stellate cell (HSC), whose activation plays a pivotal role 
in the pathogenesis of liver fibrosis. Moreover, for a better understanding of the ECS in 
general, I will give a short overview of endocannabinoids, their synthesis and degradation. 
Last but not least, the last sections highlight the role of endocannabinoids in hepatic fibrosis 
and the aim of this thesis. 
 
1.1 Pathogenesis of liver fibrosis 
Acute injury of the liver leads to a self-limited wound healing process, which restores the 
architecture and function of the liver. Increased amounts of extracellular matrix (ECM) 
proteins like collagen and elastin are expressed to replace the damaged cells. After 
cessation of acute liver injury, the parenchyma regenerates and the ECM is degraded by 
metalloproteinases (Arthur, 2000).  
If the hepatic injury persists and becomes chronic, an inflammatory and pro-fibrogenic 
environment develops. This entails a perpetuating wound healing reaction with an excessive 
deposition of ECM proteins and a failure to degrade these proteins. The consequence is a 
substitution of parenchymal cells by scar tissue. This process is called hepatic fibrosis and 
leads in the worst case to cirrhosis, the end stage of fibrosis (Bataller & Brenner, 2005; 
Friedman, 2000).  
The main causes of chronic liver disease are viral hepatitis B and C infection. According to 
the world health organization (WHO), more than 500 million people are chronically infected 
by hepatitis B or C virus (HBV; HCV, respectively), which spread primarily by direct contact 
with human blood through for example unscreened blood transfusions or re-use of needles. 
There exists an effective HBV vaccine since 1982 resulting in a significant reduction of 
chronic hepatitis B infection in infants (Chang et al., 1997). In contrast, three to four million 
persons become newly infected by HCV each year (WHO, 2002). 
Another main cause is alcohol abuse leading to alcoholic liver disease (ALD) (Farrell & 
Larter, 2006; Leon, Shkolnikov, McKee, Kiryanov, & Andreev, 2010). In industrial countries, 
ALD accounts for more than half of all cirrhotic livers (Siegmund, Dooley, & Brenner, 2005a) 
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and according to the WHO, 20 % of heavy drinkers develop fatty liver disease and 10-15 % 
of these cirrhosis (Miranda-Mendez, Lugo-Baruqui, & Armendariz-Borunda, 2010).  
In the last few decades, non-alcoholic fatty liver disease (NAFLD) arose emerging from 
increasing rates of obese patients presenting increased insulin resistance and 
hypertriglyceridaemia. After progression into steatohepatitis, this liver disease resembles 
alcoholic hepatitis occurring in non-drinkers. It was first observed 30 years ago (Ludwig, 
Viggiano, McGill, & Oh, 1980). Although only 20 % of overweight people develop NAFLD, it 
is still a severe problem through the dramatically increasing prevalence of obesity (Day, 
2005). 
 
Figure 1. Liver fibrosis results from chronic damage to the liver parenchyma due to for example 
hepatitis B or C virus (HBV or HCV, respectively) infections, alcohol abuse leading to alcoholic liver 
disease (ALD) or obesitas leading to non-alcoholic fatty liver disease (NAFLD). Upon liver injury, 
quiescent hepatic stellate cells (HSCs) activate to myofibroblast like cells. Activated HSCs are the 
main extracellular matrix (ECM) producing cells. This overproduction of ECM proteins leads to hepatic 
fibrosis and in the worst case to cirrhosis. 
 
Chronic liver diseases represent a major health problem, which is now in the top ten causes 
of mortality worldwide (Lotersztajn et al., 2005). The high mortality rate caused by chronic 
liver diseases is mainly due to hepatic cirrhosis and the resulting severe clinical 
complications.  Portal hypertension is a common consequence of cirrhosis. The blood flow 
through the portal vein is retarded by the inflamed and fibrotic tissue. Blood pressure 
increases resulting in ascites, which represent the most common complication of cirrhosis 
with 50 % mortality of patients in five years. Spontaneous bacterial infections causing 
peritonitis is seen in 30 % of patients with severe cirrhosis. The survival rate of these patients 
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is less than one year. Moreover, cirrhosis represents a risk factor for the development of 
hepatocellular carcinoma (Dong & Saab, 2008). 
Up to now, removal of the causative agent is the most effective way to treat fibrosis (Bataller 
et al., 2005; Siegmund et al., 2005a). Alcohol withdrawal, eradication of the toxic agent 
(Okazaki, Watanabe, Hozawa, Arai, & Maruyama, 2000; Sobesky et al., 1999) (Dufour & 
Oneta, 2004) or weight loss in patients with NAFLD can significantly reduce inflammation or 
even reverse fibrosis (Dixon, Bhathal, Hughes, & O'Brien, 2004). 
However, what if the removal of the causative agent cannot be achieved like chronic viral 
infections? In this case, alternative treatment options are strongly required. 
1.2 The hepatic stellate cell: good or bad guy? 
The overproduction of ECM following scarring of the liver results from an activation of 
myofibroblast-like cells. The primary source of connective tissue presents the hepatic stellate 
cell (HSC), the main fibrogenic cell type in the liver (Bataller et al., 2005; Friedman, 2000). 
HSCs are first described by Kupffer in the 19th century and play pivotal roles in the response 
to hepatic injury and fibrosis (Bataller et al., 2005; Friedman, 2004; Iredale, 2007; Wake, 
1971). 
HSCs reside in their quiescent state in the space of Disse between the hepatocytes and the 
sinusoidal endothelial cells, which are lining the liver sinusoids. They represent one third of 
the entire non-parenchymal cell population and 8-14 % of the total number of resident cells in 
the liver (Giampieri, Jezequel, & Orlandi, 1981). 
In the healthy liver, HSCs play a central role in uptake and storage of vitamin A (Wake, 
1971). Following liver injury of any etiology, HSCs activate, transdifferentiate into 
myofibroblast-like cells and start to produce high amounts of ECM proteins, which replace 
the damaged parenchymal cells (Figure 1). Kupffer cells (KCs), the resident macrophages in 
the liver, have been found to be essential for the activation of HSCs by secreting 
profibrogenic cytokines like transforming growth factor (TGF) β and by recruiting 
inflammatory cells to the side of injury (Duffield et al., 2005; Matsuoka & Tsukamoto, 1990; 
Rivera et al., 2001). After cessation of the acute damage, these inflammatory cells together 
with the HSCs degrade the extracellular tissue. Thus, after an acute injury of the liver, 
activation of HSCs is an important and beneficial step to restore liver architecture and 
function. 
If hepatic injury becomes chronic, the removal of the ECM is no longer achieved. Instead, 
HSCs, KC and recruited inflammatory cells continue to secrete proinflammatory mediators. 
HSCs produce excessive amounts of extracellular matrix proteins, which replace also the 
healthy liver parenchyma and lead to scarring of the liver (Maher, 2001) (Pinzani & Marra, 
2001). In such an environment, activated HSCs not contribute to maintain liver architecture 
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but rather destroy the whole liver cell organisation and function. 
Primary HSCs cultivated on uncoated plastic tissue culture plates display many 
characteristics of activated HSCs in vivo; they start to proliferate, loose the vitamin A stores 
and increase the cytosceletal protein expression (Friedman, 2008b). Therefore, isolation of 
HSCs is an excellent in vitro model for the examination of the role of these cells in hepatic 
fibrosis. 
Due to their pivotal role in the pathophysiology of the disease, HSCs display an interesting 
target for the treatment of hepatic fibrosis. During amelioration of liver fibrosis in rats, a 
selective cell death in activated HSCs takes place (Iredale et al., 1998). Several endogenous 
mediators including Fas ligand (FasL), tumor necrosis factor (TNF) α or nerve growth factor 
(NGF) are capable to induce cell death in HSCs (Lang, Schoonhoven, Tuvia, Brenner, & 
Rippe, 2000; Saile, Knittel, Matthes, Schott, & Ramadori, 1997; Trim et al., 2000). However, 
these mediators act on cellular receptors that are also highly expressed in hepatocytes and 
other hepatic cell populations. Thus, these endogenous mediators are unsuitable candidates 
for the treatment of liver fibrosis.  
It was recently demonstrated that the endogenous cannabinoids N-arachidonoyl 
ethanolamine (anandamide, AEA) and 2-arachidonoyl glycerol (2-AG) are highly efficient in 
inducing cell death in HSCs, but not in hepatocytes (Siegmund et al., 2007; Siegmund et al., 
2006; Siegmund, Uchinami, Osawa, Brenner, & Schwabe, 2005b). Moreover, AEA and 2-AG 
levels in the liver are significantly upregulated during fibrogenesis in vivo and can reach 
concentrations that induce cell death in HSCs in vitro (Siegmund et al., 2007). 
Based on these findings, endocannabinoids may potentially act as endogenous antifibrotic 
mediators. 
1.3 The endocannabinoid system 
The first natural cannabinoid, the main psychoactive compound of Cannabis Sativa, Δ9-THC 
(delta-9-tetrahydrocannabinol) has been isolated in 1971 (Gaoni & Mechoulam, 1971). 
Endogenous cannabinoids started to be characterised in the early 90s. Endocannabinoids, 
their receptors and the molecules that are responsible for their uptake, synthesis and 
degradation form a signalling system (endocannabinoid system, ECS) that plays pivotal roles 
in a number of physiological processes including nociception, food intake, intestinal motility 
or inflammation (Capasso et al., 2005; Di Marzo, Bifulco, & De Petrocellis, 2004; Di Marzo & 
Matias, 2005; Storr, Yuce, & Goke, 2006). Moreover, the ECS is involved in the 
pathophysiology of several diseases including atherosclerosis, fatty liver disease or liver 
fibrosis (Fisar, 2009; Osei-Hyiaman et al., 2005; Siegmund & Schwabe, 2008). 
Endocannabinoids (ECs) are endogenous ligands for the cannabinoid receptors. There are 
at least two seven-transmembrane-domain cannabinoid receptors (CB1 and CB2) that are 
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coupled to Gi/o-proteins. The CB1 receptor was cloned in 1990 and is mostly expressed in the 
central nervous system (Matsuda, Lolait, Brownstein, Young, & Bonner, 1990), but also in 
peripheral tissues including the gastrointestinal tract, the lung and the liver (Osei-Hyiaman et 
al., 2005). The CB2 receptor was cloned in 1993 (Munro, Thomas, & Abu-Shaar, 1993) and 
shows high expression levels in immune cells and peripheral tissues like tonsils and spleen, 
but is also present in the central nervous system (Brown, Wager-Miller, & Mackie, 2002; 
Klein et al., 2003; Onaivi et al., 2006). 
The N-acyl ethanolamide N-arachidonoylethanolamide (anandamide; AEA) and the 
monoacylglycerol 2-arachidonoyl glycerol (2-AG) represent the two most studied 
endocannabinoids.  AEA was discovered in 1992 and can act as an endogenous ligand for 
CB1 receptors and with low efficiency to CB2 receptors (Devane et al., 1992). Moreover, it 
can bind to transient receptor vanilloid type 1 (TRPV1) (van der Stelt et al., 2005) and to the 
G protein-coupled receptor GPR55 (Ryberg et al., 2007). 2-AG was discovered as a second 
endogenous ligand, which is a full CB1 and CB2 receptor agonist (Mechoulam et al., 1995). 
In 2001, 2-arachidonoyl glycerol ether (noladin ether) was isolated from porcine brain (Hanus 
et al., 2001). One year later it was found in amounts similar to AEA in rat tissue (Fezza et al., 
2002). It binds very weakly to the CB2 receptor but has a high affinity to CB1 receptors 
(Steffens, Zentner, Honegger, & Feuerstein, 2005). Noladin ether has anti-proliferative 
effects in prostate carcinoma cells by a cannabinoid receptor-independent pathway, but other 
functional activities are rarely known so far (Hanus et al., 2001; Nithipatikom, Isbell, Endsley, 
Woodliff, & Campbell). Nevertheless, Sugiura and colleagues could not find any noladin 
ether in rat brain (Oka et al., 2003). Although its affinity to cannabinoid receptors is not in 
discussion, its physiological role is undetermined so far. 
 Shortly after, by developing a bioanalytical method to measure anandamide in tissue, a 
substance was found with the same molecular weight than anandamide but with a shorter 
retention time. This analyte was O-arachidonoyl-ethanolamine (virodhamine), an arachidonic 
acid and ethanolamine joined by an ester linkage. In the brain, virodhamine showed similar 
concentrations to that of AEA and in peripheral tissues the levels of virodhamine are even 
higher than that of AEA. At the CB2 receptor, virodhamine acts as a full agonist. However, 
less is known about the effects of virodhamine: it produces hypothermia in mice and reflected 
vasorelexant activities in mesenteric arteries in rats (Ho & Hiley, 2004; Porter et al., 2002). 
Moreover, virodhamine causes a relaxation of human pulmonary arteries and as such could 
control the vascular tone (Kozlowska et al., 2008). Nevertheless, virodhamine has been 
shown to be partly converted to AEA, which should be taken into consideration when looking 
at virodhamine-induced effects (Saario, Savinainen, Laitinen, Jarvinen, & Niemi, 2004).  
N-arachidonoyl dopamine (NADA) was recently identified as an endogenous ligand for CB1 
receptors and TRPV1. It belongs to the endovanilloid class of endocannabinoids (Bisogno et 
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al., 2000; Huang et al., 2002). It also shows low affinity to CB2 receptors (Bisogno et al., 
2000; Di Marzo et al., 2004). In peripheral organs such as isolated bronchi or urinary bladder 
of the guinea pig, NADA showed constrictory effects mediated by TRPV1 signalling (Harrison 
et al., 2003). In contrast, NADA initiated vasorelaxant effects also via the activation of TRPV1 
and CB1 receptors in small mesenteric vessels, superior mesenteric artery or aorta in rats 
(O'Sullivan, Kendall, & Randall, 2004; 2005). Moreover, NADA induces cell death in a human 
neuroblastoma cell line and in human peripheral blood mononuclear cells via TRPV1 
activation (Davies, Hainsworth, Guerin, & Lambert; Saunders, Fassett, & Geraghty, 2009). 
However, further roles of NADA as a representative of this novel endovanilloid class of 
endocannabinoids in peripheral tissues need to be elucidated (Hu et al., 2009; Huang et al., 
2002). 
1.3.1 Endocannabinoid synthesis and degradation 
The endocannabinoids AEA and 2-AG are arachidonic acid-derived lipid mediators. Unlike 
many other signalling molecules, they are not stored intracellularly, but synthesised on 
demand in response to specific signals such as an increase in intracellular Ca2+ (Straiker & 
Mackie, 2006). AEA is produced from membrane phospholipids through hydrolysis of N-
arachidonyl-phosphatidyl-ethanolamine (NAPE) by a Ca2+-sensitive NAPE-phospholipase D 
(NAPE-PLD) (Okamoto, Morishita, Tsuboi, Tonai, & Ueda, 2004). 2-AG is produced in two 
steps via generation of diacylglycerols (DAG) from phosphatidylinositol and subsequent 
hydrolysis of DAG with arachidonate in the second position by the enzyme DAG lipase 
(DAGL) (Di Marzo et al., 1999) (Figure 2).  
Less is known about the biosynthesis of the most recent discovered endocannabinoids. 
Indeed, the biosynthetic pathway of noladin ether is unknown so far, while virodhamine is 
believed to have a synthesis pathway related to AEA due to their structural similarities 
(Porter et al., 2002) (Ho et al., 2004). The proposed mechanism of NADA biosynthesis is the 
condensation of arachidonic acid and tyrosine followed by a transformation of N-
arachidonoyl-tyrosine into NADA. This reaction is catalysed by tyrosine hydroxylase, an 
enzyme catalysing also the biosynthesis of dopamine from tyrosine (Hu et al., 2009) (Figure 
2). 
The hydrolysis of endocannabinoids, which results in the termination of endocannabinoid 
signalling, is an intracellular event. Endocannabinoids are lipophilic substances and can 
cross cell membranes by simple diffusion. However, the existence of a putative 
endocannabinoid transporter is also under discussion (Beltramo & Piomelli, 2000; Glaser et 
al., 2003). Anandamide is degraded by fatty acid amide hydrolase (FAAH) to ethanolamine 
and arachidonic acid (Cravatt et al., 1996). Pharmacological blocking of FAAH as well as 
genetic deletion leads to strongly enhanced AEA levels (Muccioli, 2010). 
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Although it has been recently shown that FAAH is also able to degrade 2-AG in vitro, 2-AG 
levels are not increased in FAAH knockout mice (FAAH-/- mice) (Muccioli; Patel et al., 2005). 
Indeed, 2-AG is mainly hydrolysed by the serine hydrolase monoacylglycerol lipase (MGL) to 
glycerol and arachidonic acid (Dinh, Kathuria, & Piomelli, 2004) (Figure 2).  
In human neocortex, virodhamine interacts with FAAH (Steffens et al., 2005) and a specific 
FAAH inhibitor attenuated the vasorelaxant effect of virodhamine suggesting an involvement 
of this enzyme in its metabolism (Ho et al., 2004). 
NADA is rapidly taken up in glioma cells by an unknown mechanism and is hydrolysed by 
FAAH but significantly slower than AEA (Figure 2). Another mechanism for deactivation of 
NADA could be the metabolism to the less potent 3-O-methyl derivative by catechol-O-
methyl transferase (COMT) (Hu et al., 2009).  
 
Figure 2. Biosynthesis and breakdown of the endocannabinoids anandamide (AEA), 2-arachidonoyl 
glycerol (2-AG) and N-arachidonoyl dopamine (NADA). AEA is synthesised by N-transacylation of a 
glycerophospholipid to phosphatidylethanolamine (PE) resulting in N-acyl-phosphatidlyethanolamine 
(NAPE). Afterwards, NAPE is transformed to AEA catalysed by an NAPE-phospholipase C (NAPE-
PLC). After synthesis, AEA is rapidly deactivated via degradation by fatty acid amide hydrolase 
(FAAH). 2-AG is synthesised from diacylglycerol (DAG) via the actions of DAG lipase (DAGL). In 
addition, 2-AG is hydrolysed by monoacylglycerol lipase (MGL) to yield arachidonic acid (AA) and 
glycerol. The proposed biosynthesis of NADA is the condensation of AA and tyrosine, which results in 
N-arachidonoyl-tyrosine. Afterwards, N-arachidonoyl-tyrosine is transformed into NADA by the 
catalysing activity of tyrosine hydroxylase (TH). Synthesis as well as degradation pathway for 
virodhamine (Viro) and noladin ether (NE) are unknown so far. To date, there are two definitive 
cannabinoid receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). Moreover, 
endocannabinoids can also bind to transient receptor potential vanilloid type 1 (TRPV1) and to the G 
protein-coupled receptor 55 (GPR55). 
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Besides the degradation pathways described above, endocannabinoids can be metabolised 
by other enzymes, for example by cyclooxygenase-2 (COX-2) into prostaglandin 
ethanolamides and prostaglandin glycerol esters (Kozak et al., 2002). Endocannabinoid 
metabolism by COX-2 represents rather a novel pathway for the biosynthesis of further lipid 
mediators with functions other than endocannabinoids than a mere deactivation mechanism.  
1.3.2 Endocannabinoid oxidation by COX-2 
In the last decade, paralleling the investigation of the endocannabinoid system, the 
characterisation of cyclooxygenases (COX) has emerged to a great field of interest. 
Cyclooygenases convert free fatty acids to prostaglandins. In the early 1990, a second 
isoform of cyclooxygenase, COX-2 was recovered (Kozak, Prusakiewicz, & Marnett, 2004; 
O'Neill & Ford-Hutchinson, 1993). While COX-1 is expressed constitutively and acts as a 
“housekeeping” protein, COX-2 shows a marginally basal expression and can be induced by 
e.g. growth factors (EGF, PDGF) or inflammatory cytokines (IL-1, TNFα) (Seibert et al., 
1997) (Herschman, 1996). However, many cells possess both isoforms, the constitutively 
active and the inducible one, resulting in no dramatic increase of prostaglandin production 
even after a strong upregulation of COX-2 (Rouzer & Marnett, 2005; 2008). Moreover, COX-
1 and COX-2 share more than 90 % sequence homology. Though what is the functional 
difference between these two oxygenases? Interestingly, COX-2 possesses an additional 
binding site. This internal pocket is conserved in all COX-2 genes sequenced up to now 
suggesting a specific function of COX-2 besides the functions shared with COX-1 (Smith, 
DeWitt, & Garavito, 2000) (Kozak, Prusakiewicz, Rowlinson, Schneider, & Marnett, 2001b). 
Indeed, the first catalytic difference of COX-1 and -2 was uncovered 1997 when COX-2 
displayed the ability to create prostaglandin ethanolamides (PG-EA) after incubation with 
AEA in vitro. This finding represents the first marked connection between COX-2 and the 
endocannabinoid system. Occasionally, COX-1 displayed no metabolism of AEA (Yu, Ives, & 
Ramesha, 1997). Shortly after, the metabolism of 2-AG by COX-2 was also investigated. 
Kozak and colleagues showed that 2-AG is metabolised by COX-2 much more efficiently 
than AEA and even arachidonic acid (Kozak et al., 2004).  
Like AEA, 2-AG is a specific substrate for COX-2, but not for COX-1 representing a selective, 
probably biological meaningful function for COX-2 (Kozak, Rowlinson, & Marnett, 2000). 
COX-2 action on 2-AG and AEA in vitro leads to the production of prostaglandin H2 glycerol 
ester (PGH2-GE) and prostaglandin H2 ethanol amide (prostamide H2, PGH2-EA), 
respectively. The unstable PGH2-GE and PGH2-EA are metabolised by different synthases to 
a set of PG-GE and PG-EA, respectively (Kozak et al., 2002) (Figure 3). 
These prostaglandin analogues are poor substrates for further oxidation steps. Thus, PG-GE 
and PG-EA are much more stable than their PG counterparts and are able to diffuse from 
their site of generation (Kozak et al., 2001a). 
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Figure 3. Conversion of 2-arachidonoyl glycerol (2-AG) and Anandamide (AEA) by an oxygenation 
pathway. 2-AG and AEA are first converted to prostaglandin H2 glycerol ester (PGH2-GE) and 
prostaglandin H2 ethanolamide (PGH2-EA, respectively. Afterwards, the prostaglandin-synthases F, E 
and D (PGFS, PGES, PGDS) metabolise the H2 derivative to the corresponding prostaglandin-
glycerolester (PG-GE) or –ethanolamides (PG-EA). 
 
Less is known about the synthesis of PG-EA and PG-GE in vivo and about their biological 
effects. The COX-2 oxygenation product PGE2-EA inhibits IL-12 and IL-23 expression in 
migroglia and macrophages. Their progenitor, AEA, exhibits similar effects. Interestingly, the 
inhibitory effect of AEA is reversible by treatment with a COX-2 inhibitor. This study suggests 
that AEA functions not directly in a cannabinoid receptor-dependent way but rather by its 
metabolism via COX-2 (Correa et al., 2008).  
PGE2-GE induces an increase in the frequency of mIPSCs in mouse hippocampal neurons. 
This contrasts with the effects of 2-AG and the prostaglandin counterpart PGE2, which both 
reduce the frequency. When hippocampal preparations are treated with the COX-2 inhibitor, 
the frequency decreases suggesting the increase is due to an increase of endocannabinoid-
derived PG-GE produced by COX-2 (Sang, Zhang, & Chen, 2006). 
In another study, AEA is shown to induce cell death in tumourigenic but not in non-
tumourigenic keratinocytes. The authors could show that AEA selectively induces cell death 
due to the overexpression of COX-2 in the tumour cells and the resulting metabolism of AEA 
to toxic PG-EA (Van Dross, 2009).  
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The socalled oxoendocannabinoids produced by COX-2 probably represent a group of 
unique signalling mediators with activities distinct from their precursors. Previous studies 
showed, that COX-2 is marginally expressed in the healthy liver. Interestingly, COX-2 
expression is strongly upregulated in the injured liver (Jeong et al. 2010) paralleled by the 
upregulation of the endocannabinoid system. Recent studies showed, that induction of COX-
2 leads to growth inhibition in HSCs, therefore having putative anti-fibrotic properties 
(Davaille et al., 2000; Gallois et al., 1998). However, the role of COX-2 during fibrogenesis is 
still under discussion. 
1.4 Endocannabinoids as key modulators in liver fibrosis 
In recent years, several studies showed that the ECS becomes activated and plays important 
roles in chronic and acute hepatic injury (Siegmund et al., 2008). This activation of the 
hepatic ECS occurs in early stages of liver disease and remains throughout later stages 
(Osei-Hyiaman et al., 2005).  
It was shown that the cannabinoid receptors CB1 and CB2 are expressed marginally or are 
even absent in the healthy liver. Chronic hepatic injury induces markedly the expression of 
these receptors (Julien et al., 2005; Teixeira-Clerc et al., 2006). Interestingly, CB1-deficient 
mice show a significant decline of fibrosis after bile duct ligation or CCl4 treatment compared 
to wild type animals. Furthermore, the CB1 inhibitor rimonabant reduced profibrogenic 
markers like α smooth muscle actin. It was suggested that these effects were caused by an 
increase in cell death and decreased proliferation of myofibroblasts (Teixeira-Clerc et al., 
2006). In contrast, CB2-/- mice display a significant increase of fibrosis after CCl4 treatment 
compared to wild type animals and CB2 receptor inhibition leads to a decrease in cell death 
and an increase in proliferation of myofibroblasts (Julien et al., 2005). These findings indicate 
for opposing effects of CB1 and CB2 receptors in the liver. Whereas the CB1 receptor displays 
pro-fibrogenic, the CB2 receptor shows anti-fibrogenic properties. This was also confirmed by 
a study recently published: Trebicka and colleagues could show that steatosis and 
fibrogenesis are increased in mice lacking the CB2 receptor and decreased in CB1 knockout 
mice (Trebicka et al. 2011). The effects reported here are mediated by cannabinoid receptors 
expressed on myofibroblasts, but it is important to keep in mind that the CB1 receptor is also 
found on endothelial cells and hepatocytes (Julien et al., 2005) (Siegmund et al., 2005b; 
Teixeira-Clerc et al., 2006). Moreover, CB2 receptors are primarily found on macrophages 
such as liver resident Kupffer cells. Thus, CB2-mediated anti-fibrogenic effects may be a 
result of its anti-inflammatory actions like suppression of pro-inflammatory factors or the 
increased production of anti-inflammatory mediators (Figure 4). Interestingly, daily cannabis 
use was found to accelerate fibrogenesis in patients with hepatitis C. Apparently, pro-
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fibrogenic CB1-mediated signals dominate over the anti-fibrotic actions of CB2 receptors 
(Hezode et al., 2005).  
Anandamide levels are increased in several disorders such as fatty liver, acute hepatitis or 
cirrhosis (Biswas et al., 2003; Osei-Hyiaman et al., 2005). Moreover, 2-AG levels are strongly 
upregulated after hepatic damage in two well-established mouse models of liver fibrogenesis, 
bile duct ligation and CCL4 treatment (Siegmund et al., 2007). It is known that 
lipopolysaccharide (LPS) increases AEA levels in macrophages (Liu et al., 2003). In hepatic 
fibrosis an elevated level of LPS has been also shown suggesting that LPS can trigger 
endocannabinoid levels in the liver (Schwabe, Seki, & Brenner, 2006). 
The upregulation of AEA was not due an increase in the synthesis pathway but rather by a 
decline in the expression of the endocannabinoid-degrading enzyme FAAH. FAAH is highly 
expressed in the parenchymal cells of the liver giving hepatocytes a crucial role in limiting 
endocannabinoid levels under pathological conditions (Siegmund et al., 2006). Whether the 
increased 2-AG amounts are caused by an increase in the production or by a decline in the 
degradation of 2-AG remains to be elucidated.  
Recent studies have shown that the regulation of cell death and proliferation of profibrogenic 
cells are one aspect of the role of endocannabinoids in fibrogenesis. HSCs are highly 
sensitive to cell death induction by exo- and endocannabinoids. The exogenous cannabinoid 
THC showed cytotoxic effects towards human hepatic stellate cells in a CB2 receptor-
dependent manner (Julien et al., 2005). 
In a primary cell culture model, it was shown that AEA and 2-AG are able to induce necrotic 
and apoptotic cell death in HSCs, respectively (Figure 4). The endocannabinoid-induced cell 
death requires membrane cholesterol and is mediated by an increase of reactive oxygen 
species (ROS). However, 2-AG as well as AEA induces cell death in a receptor-independent 
way. Hepatocytes are completely resistant to endocannabinoid-mediated cell death (Figure 
4). It is believed that less amounts of membrane cholesterol and high expression of the 
endocannabinoid-degrading enzyme FAAH in hepatocytes are responsible for the different 
susceptibility of these cell types (Siegmund et al., 2005b) (Siegmund et al., 2007). 
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Figure 4. Proposed function of the hepatic endocannabinoid system during fibrogenesis. Antagonists 
of the endocannabinoid receptor CB1 such as rimonabant have anti-fibrotic properties by inhibiting 
CB1 mediated proliferation of HSCs. Moreover, by blocking CB1 receptors on hepatocytes, hepatic 
steatosis by high fat diet is declined. Endocannabinoids like 2-AG and AEA induce cell death in HSCs 
in a receptor-independent way. Hepatocytes express the endocannabinoid-degrading enzyme FAAH, 
which leads to resistance to endocannabinoid-induced cell death. CB2 receptors are expressed on 
HSCs and inflammatory cells and activation of these receptors suppress the secretion of 
proinflammatory mediators and thus inhibit fibrogenesis (modified according to Siegmund et al., 2008). 
 
In the last few years it became more and more clear that modulation of the ECS might be 
utilised for the treatment of fibrosis. CB1 antagonism showed to have beneficial effects on 
hepatic steatosis (Despres, Golay, & Sjostrom, 2005; Osei-Hyiaman et al., 2005). Moreover, 
the anti-inflammatory effects of CB2 could be exploited by its activation with specific agonist. 
The possibility of endocannabinoids like 2-AG to induce specifically cell death in HSCs 
displays potential as antifibrotic mediators (Figure 4).  
1.5 Aim of this thesis 
The purpose of this study was the investigation of the endocannabinoid system in the injured 
and fibrotic liver. The effects of the recently identified endocannabinoids noladin ether, 
virodhamine and NADA are investigated on hepatic cell populations.  
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To reach this aim, HSCs and hepatocytes were isolated from healthy and injured livers of 
wild type and different knockout animals. Cell death induced by NADA is analysed in detail 
by a combination of pharmacological and genetic approaches. These results may be relevant 
for the design of antifibrotic therapies. 
Moreover, cellular origin and mechanisms that lead to increased hepatic 2-AG levels during 
fibrogenesis are determined. For this purpose, the expression of the synthesis as well as the 
degradation enzymes of 2-AG is examined in injured and healthy livers. Thus, modulation of 
the synthesis or the degradation pathways of 2-AG can be used to increase or decrease 2-
AG levels in the liver. 
A further aim is the investigation of the molecular pathway that underlie the different 
susceptibility of HSCs and hepatocytes toward 2-AG. A possible role for cyclooxygenase 
(COX)-2 that converts 2-AG to PG-GE is taken into account in 2-AG-induced cell death. The 
differential expression of COX-2 and the production of PG-GE is analysed in hepatocytes as 
well as in HSCs to further characterise 2-AG-induced cell death. This will achieve a better 
understanding of the role of 2-AG in the injured liver. 
In conclusion, the understanding of the role of endocannabinoid-mediated pathways in liver 
injury allows it to target various components of this system to decrease fibrogenesis in the 
liver. 
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2 MATERIAL  
2.1 Equipment 
Centrifuges Biofuge fresco, Heraeus Instruments 
Biofuge pico, Heraeus Instruments 
Biofuge stratos, Heraeus Instruments 
Sorvall Evolution RC, Kendro 
Magnetic stirrer MR 3001 K, Heidolph, Fisher  
Microplate Analyzer MRX TC II, Dynex Technologies 
pH meter inoLab, WTW  
Spectral photometer 91-ND-1000 UV/Vis, Nanodrop  
Sterilising oven Varioklav 25T, H+P Labortechnik 
Vortexer Vortex-Genie 2, Scientific Industries  
Electrophoresis gel chamber XCellSureLockTM, Invitrogen 
Blotting chamber BlotTM, Invitrogen 
Film processing machine CP1000, AGFA 
Perfusion pump Pumpdrive5201, Heidolph 
Microscope Nikon Eclipse TS 100 
Power supply PowerEase 500, Invitrogen 
Camera AxioCam MRm, Zeiss 
Laminar flow hood HeraSafe®, Kendro 
Cell culture incubator Binder 
 
2.2 Chemicals and reagents 
If not noted otherwise, all reagents used in this work were purchased from Invitrogen, Carl 
Roth, Merck or Sigma-Aldrich.  
2.3 Stimulants for cell culture 
2-arachidonoyl glycerol  (2-AG) Cayman Chemicals 
Noladin ether Cayman Chemicals 
Actinomycin D (Ac D) Sigma-Aldrich 
Anandamide (AEA) Sigma-Aldrich 
Arachidonic acid (AA) Sigma-Aldrich 
Caspase inhibitor (Z-VAD-FMK) Promega 
CB1 antagonist AM251 Tocris  
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CB2 antagonist SR144528 (SR2) Sanofi 
COMT inhibitor (OR-486) Tocris 
DL-buthionine- (S,R)-sulfoximine (BSO) Sigma-Aldrich 
Dopamine Sigma-Aldrich 
FAAH inhibitor URB597 Cayman Chemicals 
Gluthatione-ethylester (GSH-EE) Sigma-Aldrich 
Methyl-β-cyclodextrin (MCD) Sigma-Aldrich 
N-arachidonoyl dopamine (NADA) Sigma-Aldrich 
Noladin ether (NE) Sigma-Aldrich 
Prostaglandin D2 glycerol ester (PGD2-GE) Sigma-Aldrich 
Prostaglandin E2 glycerol ester (PGE2-GE) Sigma-Aldrich 
Prostaglandin F2α glycerol ester (PGF2-GE) Sigma-Aldrich 
Recombinant murine tumour necrosis factor (TNF) α R&D Systems 
TROLOX  
(6-hydroxy-2,5,7,8-tetramethylchromane-2-carbonacid) 
Calbiochem 
TRPV1 agonist Capsaicin Cayman  
TRPV1 antagonist capsazepine Sigma-Aldrich 
Virodhamine Tocris 
 
2.4 Enzymes for cell isolation 
2.4.1 HSC isolation 
Collagenase D Roche 
DNase I Roche 
 
2.4.2 Hepatocyte, KC, LSEC isolation 
Collagenase CLSII Biochrom 
 
2.5 Antibodies 
2.5.1 Primary antibodies 
Antibody against Source Obtained from Dilution 
Caspase 3 rabbit Cell Signaling 1:1000 
Catechol-O-methyl transferase (COMT) rabbit Santa Cruz 
biotechnology 
1:500 
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Cleaved Poly (ADP-ribose) polymerase (PARP) rabbit Cell Signaling 1:1000 
Fatty acid amide hydrolase (FAAH) rabbit Cayman Chemical 1:250 
Phosphorylated extracellular signal regulated 
kinase (pERK) 
rabbit Cell Signaling 1:1000 
Tyrosine hydroxylase (TH) rabbit Cayman Chemical 1:250 
α smooth muscle actin (α-SMA) rabbit Abcam 1:2000 
β-actin mouse Sigma-Aldrich 1:10000 
 
Table 1: List of primary antibodies. 
2.5.2 Secondary antibodies 
Antibody Obtained from Dilution  
Anti-rabbit Abcam 1:5000 
Anti-mouse Sigma Aldrich 1:10000 
 
Table 2: List of secondary antibodies  
 
All secondary antibodies used are linked to “horseradish-peroxidase” (HRP) for detection via 
ECL-reaction. 
2.6 TaqMan assays 
All oligonucleotides used in this work were synthesised and delivered by Applied Biosystems. 
The forward primer of each pair was labelled at the 5’ end with the fluorescent dye FAM or 
TAMRA. 
 
mRNA to detect Assay ID 
18s rRNA Normalization Standard 
COX-2 Mm00478374_m1 
DAGLα Mm00813830_m1 
DAGLβ Mm00523381_m1 
FAAH Mm00515684_m1 
MGL Mm00449274_m1 
α-SMA Mm0072512_s1 
 
Table 3: TaqMan assays  
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3 METHODS 
 
3.1 Isolation of primary hepatic cells 
The establishment of primary hepatic cell isolation and following cultivation was an important 
step for investigating the pivotal roles of different cell types in the healthy and injured liver. 
3.1.1 Animals 
C57BL/6 mice (Janvier) and male Sprague-Dawley rats (Charles River) were housed in a 
temperature-controlled environment with a 12 h light/dark cycle. They were fed with standard 
mice or rat chow, respectively, and water ad libitum. All experimental protocols of this study 
were performed in accordance with national animal care guidelines (Tierschutzgesetz 
Germany) and all procedures were approved by the local committees for animal studies 
(Regierungspräsidium Karlsruhe and Köln). 
3.1.2  Solutions 
All solutions were filtered trough a 0.22 µm bottle top filter and adjusted to pH 7.4. 
 
10x stock solution 
NaCl 80 g/l 
KCl   4 g/l 
NaH2PO4. H2O   0.882 g/l 
Na2HPO4   1.2 g/l 
HEPES   2.4 g/l 
NaHCO3   3.5 g/l 
 
                                 EGTA solution                    Enzyme solution 
10x stock solution 100 ml/l 100 ml/l 
EGTA 190 mg/l - 
Glucose 900 mg/l - 
CaCl2. 2H2O - 560 mg/l 
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                                 GBSS/A            GBSS/B 
NaCl - 8000 mg/l 
KCl 370 mg/l 
MgCl2. 6H2O 210 mg/l 
MgSO4. 7H2O 70 mg/l 
Na2HPO4 59.6 mg/l 
KH2PO4 30 mg/l 
Glucose 991 mg/l 
NaHCO3 227 mg/l 
CaCl2. 2H2O 225 mg/l 
 
3.1.2.1 HSC-specific solutions 
Pronase solution 
40 mg pronase in 80 ml enzyme solution 
Collagenase solution 
36 mg collagenase in 120 ml enzyme solution 
Pronase/collagenase solution 
30 mg pronase, 30 mg collagenase and 10 mg DNase in 100 ml enzyme solution 
Nycodenz stock solution 
8 g Nycodenz in 27.5 ml of GBSS/A 
3.1.2.2 Hepatocyte-specific solutions 
Collagenase solution 
45 mg collagenase in 120 ml enzyme solution 
Percoll solution 
50 % (v/v) Percoll in HBSS/B + 10 % FCS  
3.1.2.3 Kupffer cell-specific solutions 
Solution I 
50 mg collagenase in 10 ml HBSS/B 
Solution II 
40 mg collagenase in 10 ml enzyme solution 
Percoll solution 25 % 
5 ml Percoll and 15 ml HBSS 
Percoll solution 50 % 
7.5 ml Percoll and 7.5 ml HBSS 
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MACS-buffer 
PBS; 1 % FCS; 2 mM EDTA 
3.1.2.4 LSECs-specific solutions 
CA2+deprived medium 
L-aspartate 0.1 mM 
L-threonine 0.2 mM 
L-serine 0.3 mM 
Glycine 0.5 mM 
L-alanine 0.6 mM 
L glutaminic acid 0.9 mM 
L-glutamine 0.9 mM 
KCl 3 mM 
NaH2PO4 0.7 mM 
MgCl2 0.5 mM 
NaHCO3 24 mM 
Glucose 20 mM 
Fructose 197 mM 
 
MACS-buffer 
PBS; 1 % FCS; 2 mM EDTA 
Collagenase solution 
50 mg collagenase in 100 ml Ca2+ deprived medium 
3.1.3 Anaesthetic 
                                                                                           rat                         mouse  
Hostaket (active ingredient: Ketaminhydrochloride) 100 mg/kg bw 100 mg/kg bw 
Rompun (active ingredient: Xylazine) 10 mg/kg bw 6 mg/kg bw 
 
The appropriate quantity of Hostaket and Rompun was dissolved in 0.9 % sterile NaCl 
solution and administered by intraperitoneal (IP) injection. 
3.1.4 Isolation of primary murine hepatic stellate cells 
The isolation of hepatic stellate cells (HSCs) was conducted by in situ digestion followed by 
density gradient centrifugation which is based on the specific density of vitamin A rich HSCs 
(Friedman & Roll, 1987; Friedman, Roll, Boyles, & Bissell, 1985; Knook, Seffelaar, & de 
Leeuw, 1982). This method required high vitamin A content. Since it is known that the size 
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and also the number of lipid droplets storing vitamin A increase with age, mice older than 240 
days were used. 
After anaesthetising by IP injection, the mouse was fixed on a Styrofoam platform with the 
abdomen facing up. The abdominal cavity was opened, the intestines moved to the right and 
a 27-gauge butterfly needle was inserted into the portal vein. Immediately after, the posterior 
vena cava above was cut. 
Three different perfusion steps, which were performed with a flow-rate of 4.9 ml/min, are 
necessary to release the HSCs from liver tissue. After rinsing with EGTA solution for 3 min to 
get rid of blood cells residing in the liver sinusoids and to open the desmosomes of the cell-
cell complexes, the liver was perfused first with pronase and afterwards with collagenase 
solution for approximately 2 and 4 min, respectively. During these steps the liver blanched 
and the dark red colour changed into a yellow-cream colour.  The enzyme-treated liver was 
excised and kept on ice until livers of three to four animals were obtained. Subsequently, the 
livers were minced in collagenase/pronase solution in the laminar flow hood and incubated 
for 5 to 10 min at 37 °C under constant stirring. The resulting suspension was filtered through 
a nylon mesh (150 µm in diameter) into four 50 ml tubes and centrifuged for 7 min at 500 x g 
at 4 °C. While stepwise reducing the number of centrifugation tubes by one, the sedimented 
cells were washed twice with GBSS/B + 1 % FCS. The final pellet was resuspended in 34 ml 
GBSS/B + 10 % FCS and 13.5 ml of the Nycodenz stock solution were added (final 
concentration: 8.2 %). After centrifugation for 24 min at 1400 x g at 4 °C without break a 
whitish stellate cell-enriched fraction was obtained, collected, washed with medium, 
centrifuged at 500 x g for 7 min at 4 °C and resuspended in plating medium. 
Isolated HSCs showed 95 % purity as determined by vitamin A fluorescence two days after 
isolation. The cells were activated on uncoated plastic tissue culture dishes and were used 
on day 7 after isolation without any passaging. 
3.1.5 Isolation of primary rat hepatic stellate cells 
After anaesthetising by IP injection, the rat was fixed on a Styrofoam platform. The 
abdominal cavity was opened and an 18-gauge butterfly needle was inserted to the portal 
vein. Further procedures were performed as described in section 3.1.4. The perfusion rate 
was 15 ml/min and the perfusion times of the three different perfusion steps were three times 
longer than for primary mouse HSCs. 
3.1.6 Isolation of primary murine hepatocytes 
The isolation of primary murine hepatocytes was first described by Howard et al. 1967 and 
improved by Seglen et al. in 1976 (Howard, Christensen, Gibbs, & Pesch, 1967; Seglen, 
1976). Anaesthesia, fixation and insertion of the needle were performed as described in 
section 3.1.4. Isolation of the parenchymal cells of the liver is based on a two-step perfusion 
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process that includes rinsing with EGTA solution followed by perfusion with collagenase 
solution both at a flow rate of 8 ml/min for 5 and 10 min, respectively. Subsequently, the liver 
was excised carefully and placed on a petri dish. After mincing the liver in 40 ml GBSS/B + 
10 % FCS, the cell suspension was filtered through a 150 µm gauze into a 50 ml tube. The 
hepatocyte suspension was centrifuged at 28 x g for 5 min. After repeating this washing step, 
the pellet was resuspended in Percoll solution and centrifuged at 50 x g for 10 min at 4 °C. 
Subsequently, the viable cells pelleted and the nonviable cells floated to the top. The cell 
pellet was washed with medium at 28 x g for 5 min at 4 °C and resuspended in hepatocyte 
plating medium.  
3.1.7 Isolation of primary rat hepatocytes 
Isolation of primary rat hepatocytes was conducted as described in section 3.1.6. The rat cell 
isolation requires a perfusion rate of 15 ml/min and the perfusion times for the EGTA- and 
collagenase solutions for primary rat hepatocytes were 10 and 30 min, respectively. 
 
 
Figure 5. Isolation of primary hepatic cells by in situ perfusion. After fixation of the animal, the 
abdominal wall is cut in a longitudinal line (A) and the intestines are gently moved to the side (B). A 
cannula is inserted in the portal vein and fixed with a threat silk (C). During the perfusion, the liver 
blanched from the typical dark red  (D) into a yellowish colour (E). The cell-cell contacts are 
destroyed by perfusion with enzymes. Thus, the liver becomes spongy and achieved a bigger volume 
(F). After the perfusion, the liver is transferred into a 10 cm dish (G). 
 
3.1.8 Isolation of primary murine Kupffer cells 
After sacrificing the mouse by cervical dislocation, the animal was fixated and the perfusion 
was conducted as described in section 3.1.4. Thereafter, the perfusion of solution I was 
performed at a perfusion rate of 4 ml/min for 30 sec. Subsequently, the liver was excised and 
transferred to a 50 ml tube containing solution II until 3 livers were obtained. The liver cells 
were dissociated mechanically in solution II in a laminar flow hood, transferred in a 50 ml 
tube and incubated for 17 min under constant shaking with a speed of 250 rpm. Afterwards, 
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the suspension was passed through a filter (250 µm in diameter), 40 ml HBSS/B were added 
and centrifuged at 50 x g for 2 min at 4 °C. The supernatant was collected, centrifuged at 800 
x g for 10 min at 4 °C and the resulting pellet was washed by repeating the centrifugation 
step after adding 40 ml HBSS/B. The cells were resuspendend in 10 ml PBS, layered on the 
top of a two-step Percoll gradient (25 % vs. 50 %, 15 and 20 ml, respectively) and 
centrifuged at 1350 x g for 30 min at 4 °C. The interface between the upper and the lower 
cushion was collected, washed with MACS-buffer and centrifuged at 800 x g for 10 min at 4 
°C. Subsequently, the cells were counted, labelled with CD11b microbeads (10 µl beads/ 1 x 
107 total cells) and incubated for 20 min at 4 °C. After centrifugation at 300 g for 10 min, the 
cells were resuspended in MACS buffer (up to 1 x 108 cells/ml) and filtered through a nylon 
mesh (30 µm in diameter). Afterwards, the cells were sorted magnetically by autoMACS. The 
MACS sorting was performed by Frank A. Schildberg, Institute of Molecular Medicine and 
Experimental Immunology, University of Bonn.  
3.1.9 Isolation of primary murine liver sinusoidal endothelial cells (LSECs) 
Frank A. Schildberg, Institute of Molecular Medicine and Experimental Immunology, carried 
out the isolation of primary murine LSECs. 
After sacrificing the mice by cervical dislocation, fixation and preparation of the animal as 
described in section 3.1.4, the liver was perfused with the collagenase solution at a perfusion 
rate of 4 ml/min until up to 10 livers were obtained. The livers were minced well in a laminar 
flow hood and the resulting suspension was incubated in a rotary water bath at 240 rpm for 
20 min at 4 °C. After shaking, the suspension was passed through a filter (mesh size 250 µm 
in diameter) and washed twice with HBSS/B (300 x g for 10 min at room temperature). 
Subsequently, the pellet was resuspended in 16.5 % Nycodenz, overlaid carefully with 1 ml 
HBSS/B and centrifuged at 1400 x g for 20 min at 20 °C without brake. The LSECs were 
recovered from the top layer and washed once with MACS buffer (300 x g for 10 min). 
Afterwards, the cells were counted and labelled with anti-LSEC-beads (10 µl beads/ 1 x 107 
total cells). The next steps were conducted as described previously in section 3.1.8. 
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3.2 Animal models for liver fibrosis 
3.2.1 Carbon tetrachloride- (CCL4-) induced liver injury 
Liver damage was induced in male C57BL/6 mice (n=4) by CCL4 inhalation three times per 
week over five weeks. The administration was conducted as follows: 
 
 
Moreover, the animals received phenobarbital (Luminol; 0.5 g/l) orally supplemented to the 
drinking water. This led to an increase of CCl4-toxicity resulting in accelerated development 
of liver injury. After the experimental period, the animals were sacrificed and the liver was 
excised for protein isolation. The experimental procedure for CCl4-intoxication was 
conducted by Dr. Jonel Trebicka, Department of Medicine I, University Hospital Bonn. 
3.2.2 Bile duct ligation in mice 
While anesthetising the animal with isoflurane via inhalation, the abdomen was opened by a 
midline incision under sterile conditions. The bile duct was carefully isolated, ligated twice 
and cut between the ligatures. Sham operated animals without ligation of the bile duct served 
as controls. The abdominal musculature and the skin incision were closed with absorbable 
suture. Mice were treated with a subcutaneous dose of carprofen®  before and after surgery 
for analgesia. Seven or 14 days after surgery the mice were sacrificed by cervical dislocation 
and the livers were excised for protein and RNA isolation. 
3.3 Cell culture methods 
All procedures with cells were performed under sterile conditions in a laminar flow hood. 
3.3.1 Cell counting 
Cell concentrations were determined with a Neubauer counting chamber. The cell 
suspension was diluted and –after adding trypan blue to a final concentration of 0.1 % to 
distinguish viable from non-viable cells- introduced to the chamber. Each large square 
consists of 9 small squares and has a surface area of 1 mm2 and a depth of 0.1 mm, which 
gives a defined volume of 0.1 mm3. The following calculation gives the cell number per ml: 
Cells/ml = average count/square x dilution factor x 104 
Week Time span Cycle number 
1 1 min 1 
2 1.5 min 1 
3 2 min 1 
4 2 min 2 
5 2 min 2 
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3.3.2 Culturing of primary hepatic cells 
Cells were incubated in a humidified incubator at 37 °C in an atmosphere of 5 % CO2/air. 
3.3.2.1 Coating of plastic tissue culture dishes 
The rat-tail collagen type I was used at a 1:50 dilution in 1 % acetic acid. The surface of the 
required cell tissue culture plates were covered with the collagen solution and incubated for 
30 min at room temperature under constant shaking. After washing the plates three times 
with HBSS/B, the dishes were ready to use or were stored up to four weeks at 4 °C. 
3.3.2.2 Culturing of primary HSCs  
After isolation, cells were cultured on plastic culture dishes in DMEM supplemented with 10 
% FCS and 1 % penicillin/streptomycin as previously described (Bataller et al., 1997). The 
medium was replaced every 48 h.  
3.3.2.3 Culturing of primary hepatocytes 
Plating medium Stimulation medium 
Waymouth medium RPMI medium 
10 % FCS -  
1 % penicillin/streptomycin 1 % penicillin/streptomycin 
1 % glutamine 1 % glutamine 
1 mM insulin 1.5 mM insulin 
100 µM dexamethason  1 % transferrin/selenium mix 
 
Cells were cultured on plastic tissue culture dishes with rat-tail collagen (see 3.2.2.1) in 
plating medium for 4 h. Afterwards, the cells were washed three times with HBSS/B and 
incubated in stimulation medium over night. 
3.3.2.4 Culturing of primary KCs 
Cells were cultured on plastic culture dishes with rat-tail collagen (see 3.2.21) in DMEM 
supplemented with 10 % FCS and 1 % penicillin/streptomycin. The cells were used latest 48 
h after plating. 
3.3.2.5 Culturing of primary LSECs 
Cells were cultured on coated plastic culture dishes (see 3.2.2.1) in DMEM with 10 % FCS, 2 
% glutamine and 1 % penicillin/streptomycin. 
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3.3.3 Stimulation experiments 
Cells were serum-starved with DMEM containing 0.5 % FCS over night and were treated with 
the appropriate substance for stimulation or with vehicle.  
3.3.4 Adenoviral infection procedures 
3.3.4.1 Adenoviral construction  
The adenoviruses used were a gift from Schwabe, Columbia University, NY, USA and were 
constructed as previously described in Siegmund et al. 2006. Mouse fatty acid amide 
hydrolase (FAAH) was excised from a pcDNA 3.0 and inserted into an AdTrack vector via 
XbaI and KpnI sites. After linearizing the vector using PmeI, the AdTrack was electroporated 
into competent BJ 5183-AD1 bacteria, which contain AdEasy1 (Stratagene, La Jolla, CA). 
The recombinants were linearized using PacI and transfected into HEK293 cells. Subsequent 
lysing the cells 10 day later, new HEK293 were infected and these lysates were purified on a 
CsCl density gradient (Siegmund et al., 2006). 
3.3.4.2 Adenoviral amplification 
For amplification of the viruses, HEK293 cells were infected and incubated until the 
cytopathic effect was complete (3-5 days). After harvesting, the cells were centrifuged at 500 
x g for 7 min at 4 °C. The resulting pellet was frozen and thawed five times and subsequently 
resuspended in DMEM. 
3.3.4.3 Adenoviral infection 
Primary HSCs were infected with the FAAH expressing adenovirus AdFAAH or the AdTrack-
based green fluorescent protein (GFP)-expressing control adenovirus Ad5GFP at a 
multiplicity of infection of 50, achieving transduction rates of at least 90 %. After 12 h, the 
medium was exchanged and stimulated with either NADA or AEA 24 h later. 
3.3.5 Detection of reactive oxygen species (ROS) by CM-H2DCFDA 
fluorescence 
CM-H2DCFDA is a cell-permeant indicator for reactive oxygen species (ROS), which is 
nonfluorescent until removal of the acetate groups by oxidation within the cell. After diluting 
CM-H2DCFDA with DMSO, the dye was used at a final working concentration of 6 µM. After 
adding to the medium, the cells were incubated at 37 °C for 30 min and washed with PBS to 
avoid artificial stainings. Following stimulation with the substance of interest, the fluorescent 
signal was immediately measured in an ELISA plate reader at a wavelength of 492 nm at 
different time points. 
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3.3.6 Wound healing assay 
HSCs were cultured to confluence (> 90 %) in 6-well plates. After starvation with DMEM 
containing 0.5 % FCS for 12 h, a 2-mm-wide linear wound in the cell monolayer was created 
using a white pipette tip. Cells were treated daily with sublethal concentrations of NADA or 
vehicle only. Cell migration into the wound was detected using a phase-contrast microscope 
at day 0, 4 and 6. 
3.3.7 Detection of cell death  
3.3.7.1 Lactate dehydrogenase (LDH) assay  
The lactate dehydrogenase (LDH) assay (Cytotoxicity Detection Kit, Roche Apllied Science) 
is a colorimetric assay for the quantification of cell death based on the measurements of 
lactate dehydrogenase (LDH) released from the cytosol of damaged cells in the supernatant. 
Cells were serum-starved over night and treated with the substrate of interest or vehicle. 
After collecting the culture medium at different timepoints, 50 µl of the supernatant were 
transferred into a 96-well plate in triplicates and incubated with 50 µl of the reaction solution 
(prepared according to the manufacturer’s instructions) for 30 min at room temperature. 
To calculate the percentage of cytotoxicity, the following three control reactions had to be 
performed in each experimental setup: The background control (1), which contains only 
medium, the low control (2), the supernatant of untreated cells reflecting the spontaneous 
LDH release, and the high control (3) giving the maximum LDH release. The measurement 
was conducted at a wavelength of 490 nm in an ELISA plate reader followed by calculation 
of percentage of cell death:   
 
cytotoxicity (%) =  100 / (high control – low control)  x (sample – low control)  
 
3.3.7.2 Annexin V/propidium iodide staining 
The principle of the annexin V/propidium iodide staining assay (Annexin-V-FLUOS staining 
Kit, Roche Applied Science) is the analysis of phosphatidylserine, which is translocated in 
apoptotic cells from the inner part of the plasma membrane to the outer layer, by Annexin V 
staining. Propidium iodide (PI) stains the DNA of leaky necrotic cells that allows the 
differentiation of apoptotic and necrotic cell death. 
For this assay, the cells were washed first with PBS and afterwards incubated with Annexin 
V-Fluorescein in a HEPES buffer containing PI according to the manufacturer’s protocol. The 
cells were analysed under a fluorescence microscope. 
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3.3.8 Detection of PGD2-GE  
The assay is based on the conversion of the chemically unstable prostaglandin D2 (PGD2) to 
a stable MOX derivative (Prostaglandin D2-MOX EIA Kit, Cayman Chemicals). Hepatocytes 
and HSCs were plated in 24-well plates and treated with 50 µM 2-AG or vehicle for 12 h. The 
prostaglandin glycerol ester D2 (PGD2-GE) concentration was measured by PGD2-MOX EIA 
(Cayman Chemical) Kit according to the manufacturer’s protocol with reference to a PGD2-
MOX EIA standard provided by the manufacturer. This kit is unable to distinguish between 
PGs and PG-GEs and therefore PGD2 and PGD2-GE were quantified without distinguishing 
prostaglandins from their glycerol ester derivative. 
3.4 Biomolecular methods 
3.4.1 RNA isolation 
RNA was isolated from cultured cells or frozen liver tissue. The tissue or the cells were 
homogenised in Trizol (100mg tissue/1 ml Trizol or 10 cm2 cell-tissue layer/ 1ml Trizol, 
respectively). After centrifugation for 10 min at 12,000 x g at 4 °C, 50 µl BCP were added to 
500 µl supernatant, vortexed for 60 sec and incubated at room temperature for 3 min. The 
centrifugation step was repeated and after subsequent transfer of the aqueous phase to a 
fresh tube, 250 µl isopropanol were added. The mix was shortly vortexed, incubated at room 
temperature for 10 min and centrifuged again under the same conditions. The resulting RNA 
pellet was washed once with 1 ml 75 % ethanol (12,000 x g; 10 min; 4 °C) and after 
discarding the supernatant, the dry RNA pellet of cell- or tissue-isolation was dissolved in 30 
or 100 µl DEPC water, respectively. After incubation for 15 min at 55-60 °C the RNA 
concentration was determined. 
3.4.2 Determination of RNA concentration 
The concentration of RNA was determined by measuring the absorbance at 260 nm (A260) in 
a spectrophotometer. An absorbance of 1 unit at 260 nm corresponds to 40 µg of RNA per 
ml (A260 = 1 ⇒ 40 µg). The ratio of the readings at 260 nm and 280 nm (A260/A280) provides 
an estimate of the purity of RNA regarding contaminants that absorb in the UV, such as 
protein. Pure RNA has an A260/A280 ratio of 1.8 to 2.0. 
3.4.3 Reverse transcriptase polymerase chain reaction (RT-PCR) 
The reverse transcriptase polymerase chain reaction (RT-PCR) is a method used to amplify 
cDNA copies of RNA.  
For each reaction, 2.5 µg RNA were used and the master mix was prepared for each 
reaction as follows: 
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0.1 M DTT 2 µl 
5x first strand buffer (Invitrogen) 4 µl 
H2O 1 µl 
dNTPs (10 mM each) 1 µl 
Final volume/sample 8 µl 
After adding water to the RNA up to 8 µl, 1 µl oligo(dT) solution was added and cDNA 
synthesis was conducted as follows: 
 
70 °C 10 min 
  4 °C 3 min 
add 8 µl of master mix 
 42 °C 2 min 
   4 °C 3 min 
add 1 µl of reverse 
transcriptase 
42 °C 60 min 
70 °C 15 min 
4 °C 10 min 
 
The reaction mix was filled up with water to a final volume of 100 µl. 
3.4.4 Real-time reverse transcription-PCR (real-time RT-PCR) using TaqMan 
Gene expression assays 
The real-time RT-PCR is used to quantify the expression of a gene of interest. The TaqMan 
method uses an oligonucleotide, which is labelled at the 5´ end with a fluorescent group 
(FAM or VIC) and at the 3´ end by a quenching group (TAMRA or MGB). Primers for the 
targeted sequence and the oligonucleotides are added to the PCR. When the quenching and 
the fluorescent group are close together, the TAMRA or MGB absorb the emission of the 
FAM or VIC dye, respectively, and the fluorescence signal is low. During the PCR, the 
5´⇒3´exonuclease activity of the polymerase cleaves the fluorescent part from the 
oligonucleotide and the signal can be detected. The amount of DNA that is synthesized is 
proportional to the intensity of the fluorescence detected (Russel, 2001). 
5 µl 2x TaqMan gene expression master mix and 0.5 µl 20x TaqMan assay were mixed 
together with 2.5 µl Rnase/DNase free water and 2 µl cDNA sample were added in a 384well 
plate.  
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Quantitative RT-PCR was conducted as follows: 
 
95 °C 10 sec 1x 
95 °C 15 sec 
60 °C 60 sec 
 
40x 
 
3.5 Biochemical methods 
3.5.1 Protein isolation 
3.5.1.1 Lysis buffer 
Karnovsky lysis buffer  
 10 mM Tris 
 50 mM NaCl 
 50 mM EDTA 
 30 mM Na4P2O7 
Adjusted pH to 7.5 
 0.5% Triton-X-100 
 
Immediately before use protease inhibitor tablets (1 tablet/10 ml lysis buffer, complete Mini, 
Roche) were added to the lysis buffer.  
3.5.1.2 Protein isolation out of tissue 
Freshly removed ore thawed liver tissue were first suspended in three volumes of Karnovsky 
buffer. The homogenisation was carried out at 0 °C with a plastic homogenizer by up and 
down movement until removal of all big tissue pieces. A sonification treatment was 
performed six times of 10 seconds. After a centrifugation step for 10 min at 4 °C at 12,000 g, 
the protein concentration of the sample was determined. 
3.5.1.3 Protein isolation out of cell culture 
After removing the medium, Karnovsky buffer was added to the wells (100 µl/ 6-well) and the 
cells were scraped by pipetting up and down with a 1 ml pipette tip. After transferring into an 
Eppendorf reaction tube, the cell suspension was sonified 6 times for 5 seconds. After 
centrifugation for 10 min at 4 °C at 12,000 x g, the protein concentration of the sample was 
determined. 
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3.5.2 Determination of protein concentration by BCA Protein Assay Kit 
(Pierce) 
The BCA Protein Assay Kit is a method for colorimetric detection of total protein based on 
bicinchoninic acid (BCA). Protein concentrations are determined with reference to the 
standard of bovine serum albumin (BSA) standard. The determination of protein 
concentration was conducted according to the manufacturers protocol and measured at a 
wavelength of 592 nm. 
3.5.3 Sample preparation for western blotting 
The samples were suspended with 6x SDS sample buffer and heated at 95 °C for 10 min to 
ensure protein denaturation.  
 
Afterwards, the samples were ready for Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). 
3.5.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a method that 
allows the separation of the protein samples of interest. The proteins are electrophoretically 
separated based on their weight. The electrophoresis was conducted at 200 Volt for 40 min 
in running buffer (NuPAGE SDS Running Buffer 20x, Invitrogen). NuPAGE 4-12 % Bis-Tris 
gels (Invitrogen) were used. The molecular weight marker Novex® Sharp Standard 
(Invitrogen) was used for the confirming of protein transfer and the molecular weight 
orientation. 
3.5.5 Western blot 
In a western blot, the separated sample proteins are electrophoretically transferred from a 
polyacrylamide gel onto a nitrocellulose membrane and the subsequent immuno-detection of 
the protein of interest. 
3.5.5.1 Wet blotting 
Proteins separated by SDS-PAGE were transferred from the gel to a nitrocellulose 
membrane (Whatman) using a “wet” electrophoretic transfer system in transfer buffer 
(NuPAGE transfer buffer 20x, Invitrogen with 10 % methanol/gel). After SDS-PAGE, the gel 
200 mM 1.5 M Tris-HCl pH 6.8 
8 % SDS 
40 % glycerol 
0.4 % bromphenol blue 
6x SDS sample buffer 
400 mM 1 M DTT 
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and the membrane were saturated with transfer buffer and sandwiched between saturated 
filter paper pads and plastic plates as follows: 
 
2 x Blotting Pad 
Filter Paper 
Transfer Membrane 
Gel 
Filter Paper 
Blotting Pad 
Filter Paper 
Transfer Membrane 
Gel 
Filter Paper 
2 x Blotting Pad 
 
The transfer was performed in a blotting tank (Invitrogen) for 1 h at 30 Volt constant with an 
expected current start of 170 mA and an ending current of 110 mA. 
3.5.5.2 iBlot® Gel Transfer Stacks  
The Western blot using the iBlot® Gel Transfer Stacks (Invitrogen) was conducted according 
to the manufacturer’s instructions. 
3.5.5.3 Detection 
For the detection of the proteins of interest, following solutions have to be prepared: 
 
After western blot transfer of the proteins to the nitrocellulose membrane, the membrane was 
blocked for 1 h in blocking solution at room temperature. The primary antibody was diluted in 
10 mM Na2HPO4 
2 mM KH2PO4 
137 mM NaCl 
2.7 mM KCl 
10x PBS (phosphate-buffered saline) 
Adjusted to pH 7.4 (hydrochloride acid) 
100 ml/l 10xPBS PBST (phosphate-buffered saline 
Tween20) 0.05 % Tween 20 
PBST  Blocking solution 
5 % milk powder 
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blocking solution to the appropriate concentration and the blot was incubated over night at 4 
°C. The membrane was then washed three times with PBST for 10 min. Incubation of the blot 
with the secondary antibody that was conjugated to horseradish peroxidase was carried out 
for 1-2 h at room temperature. The membrane was washed again for three times 10 min with 
PBST prior to detection. 
For this purpose, the membrane was incubated with ECL western blotting substrate (Pierce) 
for 1 min and the chemiluminiscent signal was visualized by exposure of Hyperfilm ECL 
films.  
Where indicated, the intensities of the detected bands were evaluated densitometrically 
using ImageJ (NIH, Bethesda, MD). 
3.5.6 Reprobing of western blot membranes 
Prior to reprobing the membrane with different antibodies, the previous antibody had to be 
removed. Therefore, the membrane was incubated twice in stripping buffer on a horizontal 
shaker for 30 min at room temperature and washed with PBST (three times for 5 min). After 
blocking the blot for 1 h with blocking solution, a new primary antibody could be applied as 
described. 
3.6 Statistical analysis 
All data represent the mean of three independent experiments ± standard error of the mean 
(SEM), if not otherwise stated. For the determination of statistical significance, unpaired 
Student’s t-test was performed using GraphPad Prism (Version 4.0, GraphPad Software, 
Inc.). P values of <0.05 (*) were considered to be statistically significant, values of < 0.001 
(**) were considered to be statistically highly significant.  
 
 
 
0.2 M glycine 
0.1 % SDS (w/v) 
1 % Tween 20 (v/v) 
Stripping buffer 
pH to 2.4 
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4 RESULTS 
4.1 Isolation of hepatic stellate cells 
Primary hepatic stellate cells (HSCs) undergo activation on uncoated plastic culture dishes, 
which is similar to the response of these cells to hepatic injury in vivo. Thus, isolation of 
primary HSCs represents an excellent in vitro model to study the role of those cells during 
hepatic fibrosis (Friedman, Roll, Boyles, Arenson, & Bissell, 1989). The isolation was initially 
conducted in rats due to the bigger size of the animals and thus to a higher number of cells. 
The need of using knockout mice with a deletion of a specific gene required the isolation 
murine primary stellate cells. 
4.1.1 Primary hepatic stellate cells activate on uncoated plastic culture dishes 
Before starting the experiments, the purity and also the activation state of the isolated 
primary hepatic stellate cells was determined. After plating the cells on uncoated plastic 
culture dishes, the cells became adherent within the first six hours (Figure 6A). On the first 
two days, the cells contained a high amount of vitamin A droplets, a characteristic 
phenotypical feature of unactivated HSCs (Figure 6B). These lipid droplets exhibit a rapidly 
fading blue-green autofluorescence under UV-light (330 nm), which is also used to examine 
the purity of the isolated HSCs (Friedman, 2008b). The purity of HSC preparations was over 
90 %, which was estimated by autofluorescence on day 2 after isolation (Figure 6 B). Starting 
from day two, the stellate cells underwent a transformation and developed a star-like shape. 
The cell density increased compared to day one since the cells started to proliferate (Figure 
6A). 
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Figure 6. (A) Phase contrast images of HSCs were taken at the indicated time points after isolation. 
(B) Vitamin A autofluorescence of the lipid droplets of HSCs two days after isolation was visualised 
under UV light at a wavelength of 330 nm.  
 
In addition, typical for myofibroblasts, the cells expressed α smooth muscle actin (α-SMA) on 
day 7, which was not observed in freshly isolated cells. Due to its absence in other resident 
cells in the liver, expression of α-SMA represents a reliable marker of stellate cell activation 
(Schmitt-Graff, Kruger, Bochard, Gabbiani, & Denk, 1991; Serini & Gabbiani, 1999). The 
expression of α-SMA was analysed on mRNA level by quantitative RT-PCR (Figure 7A) and 
on protein level by western blotting (Figure 7B). 
 
 
 
Figure 7. (A) Relative gene 
expression levels of α-SMA from 
freshly isolated murine hepatic 
stellate cells (d0) and from cells 
seven days after isolation (d7) 
were examined by quantitative RT 
PCR. Shown is fold of expression 
of d0 after normalization to 18s. 
**p<0.001 vs. d0. (B) α-SMA 
protein levels were determined by 
western blotting with antibodies 
against α-SMA and β-actin. 
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4.2 Investigation of the effects of noladin ether, virodhamine and 
NADA on liver cells 
It was previously shown that the endogenous cannabinoid AEA blocks proliferation and 
induces cell death in hepatic stellate cells but not in hepatocytes. However, the effects of 
other endocannabinoids such as virodhamine (Viro), noladin ether (NE) and N-arachidonoyl 
dopamine (NADA) on hepatic stellate cells have not been investigated so far. 
4.2.1 Virodhamine, noladin ether and N-arachidonoyl dopamine induce cell 
death specifically in HSCs but not in hepatocytes 
Since HSCs are the predominant cellular target of endocannabinoids (ECs) in the injured 
liver (Julien et al., 2005; Siegmund et al., 2007; Siegmund et al., 2005b; Teixeira-Clerc et al., 
2006), the potential antifibrotic effects of noladin ether (NE), virodhamine (Viro), N-
arachidonoyl dopamine (NADA) on these cells were investigated. 
NADA as well as the two other ECs rapidly and dose-dependently induced cell death in 
primary rat HSCs (Figure 8). After 2 h of stimulation, NADA significantly induced cell death in 
34, 53 and 69 % of the cells at concentrations of 25, 50 and 100 µM, respectively. Moreover, 
HSCs underwent cell death starting at a concentration of 10 µM NADA after treatment of 4 h. 
Cell death reached a plateau level after 4 h at NADA concentrations of 50 µM and higher. 
HSCs treated with NADA concentrations lower than 10 µM did not undergo cell death (Figure 
8A). 
Similar results were also obtained when the cells were stimulated with virodhamine and 
noladin ether. Virodhamine showed strong cytotoxic effects starting at a concentration of 25 
µM and the percentage of cell death maintained plateau levels at this concentration after 4 h 
of stimulation. Concentrations of 10 µM or lower showed no effects (Figure 8B). In contrast, 
noladin ether had a much stronger effect. After a stimulation time of 2 h, a concentration of 
10 µM was sufficient to induce cell death in HSCs of 40 % compared to vehicle treated cells 
and after 4 h even 5 µM were adequate to reach cell toxicity of 53 % (Figure 8C). 
To exclude possible effects of the endocannabinoids on parenchymal cells of the liver, 
primary hepatocytes were exposed to increasing concentrations of NADA, virodhamine and 
noladin ether for 16 h. In contrast to HSCs, primary hepatocytes showed no signs of cell 
death up to concentrations of 100 µM although the incubation time was four times longer 
(Figure 8). Taken together, NADA, virodhamine and noladin ether selectively induced cell 
death in HSCs but not in hepatocytes. 
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Figure 8. Primary rat HSCs and primary rat hepatocytes were serum-starved for 12 h and treated with 
the indicated concentrations of NADA (A), virodhamine (B), noladin ether (C) or vehicle (-) for the 
indicated time intervals. Cell death was determined by measuring the release of LDH into the media. 
Cell death was measured by LDH assay. *p<0.05, **p<0.001 vs. vehicle treatment. 
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4.2.2 Hepatocytes, but not HSCs express the rate-limiting NADA-generating 
enzyme tyrosine hydroxylase 
The mechanism of virodhamine and noladin ether synthesis is unknown so far (Piomelli, 
2003). For this reason, only the expression of the putative NADA-generating enzyme, 
tyrosine hydroxylase (TH) (Hu et al., 2009; Huang et al., 2002), was examined by western 
blot (Figure 9A). TH was expressed in healthy liver as well as in injured and fibrotic liver of 
wild type mice that have been intoxicated with CCL4-inhalation for five weeks. TH was found 
in hepatocytes but not in HSCs (Figure 9B) leading to the conclusion that hepatocytes but 
not HSCs are able to produce NADA in normal and diseased states of the liver. As a result of 
this finding, NADA-induced cell death was further investigated.  
 
 
 
Figure 9. (A) Male C57BL/6 
mice (n=4) underwent CCl4 
administration by inhalation  
three times a week for five 
weeks to induce fibrosis. TH 
expression was compared to 
control mice (n=4) by western 
blotting. (B) Protein levels in 
hepatocytes and HSCs of TH 
were determined by western 
blotting. A strong expression of 
TH was observed in 
hepatocytes.  
 
4.2.3 NADA induces necrosis in activated HSCs 
After the discovery that NADA is able to induce pronounced cell death in activated HSCs, the 
question whether NADA-induced cell death is apoptotic or necrotic was further to confirm.  
Primary HSCs were treated with NADA, AEA or tumour necrosis factor α (TNFα) and 
actinomycin D (ActD) as a positive control. The cells were stained with a combination of 
annexin V (AnnV), which binds to phosphatidylserine in the membrane of apoptotic cells, and 
propidium iodide (PI), a marker for necrotic cell death. While the treatment with TNFα/Act D 
showed strong Ann V staining, AEA- as well as NADA-treated stellate cells did not show Ann 
V binding. In contrast, a strong nuclear PI staining was observed indicating necrotic cell 
death induced by NADA (Figure 10A). Moreover, HSCs were prestimulated with a specific 
caspase inhibitor (Z-VAD-FMK) prior to stimulation with NADA or TNFα/ActD. While 
pretreatment with the caspase inhibitor resulted in 20 % less cell death induced by 
TNFα/ActD, NADA-induced cell death was not blocked by the costimulation (Figure 10B). 
These findings underline the necrotic model of NADA-induced cell death in HSCs. 
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Figure 10. (A) Rat HSCs were serum-starved 
for 12 h and treated with either 25 µM NADA 
or AEA for 4 h or with TNFα(30 ng/ml)/ActD 
(0.2 µg/ml)  for 16 h as a positive control for 
apoptotic cell death. Apoptotic cell death was 
indicated by green fluorescence of annexin V 
(AnnV). Necrotic cell death was shown by red 
staining of the nuclei by propidium iodide (PI). 
(B) Rat HSCs were pretreated with the 
caspase-inhibitor Z-VAD-FMK (20 µM) 30 min 
before stimulation with NADA (25 µM) or 
TNFα/ActD. Cell death was measured by LDH 
assay. *p<0.05 vs. TNFα/Act D alone. 
 
4.2.4 Sublethal doses of NADA reduce proliferation and inhibits activation of 
HSCs 
To examine if nanomolar concentrations of NADA can prevent activation of primary HSCs, 
freshly isolated stellate cells were treated daily with vehicle or NADA at concentrations of 100 
nM or 1 µM for seven days. Afterwards, α-SMA expression as a marker of stellate cell 
activation was determined. Treatment with 1 µM NADA inhibited α-SMA expression on day 3 
and 7 after stimulation. Compared to that, no reduction of stellate cell activation was 
observed at a concentration of 100 nM (Figure 11A). 
To confirm the anti-proliferative effect, phosphorylation of ERK (pERK), which is used as a 
marker for the induction of proliferation, was examined. Therefore, HSCs were incubated 
with 10 % fetal calf serum (FCS) in the culture media and afterwards treated with 100 nM 
NADA. A strong induction of ERK phosphorylation was observed directly after FCS 
stimulation. NADA was shown to strongly diminish the phosphorylation of ERK, thus showing 
anti-proliferative capacity on activated HSCs (Figure 11B). 
B 
A 
Results  39 
A 
 
 
           
B
 
 
 
 
 
 
Figure 11. (A) Freshly isolated primary rat HSCs were treated daily with 100 nM or 1 µM NADA 
directly after stimulation and cells were harvested at the indicated time points. Western blot was 
performed with antibodies directed against α-SMA and β-actin. Densitometric quantifications are 
shown in means of relative densitometric units ± SEM compared to α-SMA expression after vehicle 
treatment at the respective timepoints (day 3 and 7). *p<0.05 vs. vehicle (B) HSCs were cultured with 
DMEM containing 10 % FCS and treated with NADA (100 nM) at the indicated times. Western blot 
was performed with antibodies directed against pERK and β-actin. 
 
4.2.5 NADA-induced death in HSCs occurs independently of the 
endocannabinoid receptors CB1, CB2 or TRPV1 
Endocannabinoids induce various physiologic events via cannabinoid or vanilloid receptors. 
NADA has been shown to be a full agonist of CB1- as well as TRPV1 receptors and to a 
lesser extent of CB2 receptors (Bisogno et al., 2000; Huang et al., 2002). Using 
pharmacological and genetic approaches, the involvement of the receptors in NADA-
mediated cell death was investigated. Although CB1, CB2 and TRPV1 receptors are 
expressed in HSCs (Siegmund et al., 2005b), neither AM251, a specific antagonist of CB1, 
nor SR144528, a specific antagonist of CB2, nor capsazepine, a specific antagonist of 
TRPV1, showed cytoprotective effects after NADA-stimulation, indicating independence of 
these receptors (Figure 12A). Accordingly, activated primary HSCs isolated from wild type 
and mice lacking the CB1 receptor and the CB2 receptor (CB1-/-/CB2-/-) were equally 
susceptible toward NADA-mediated cell death (Figure 12B). To provide further evidence of 
the receptor-independent induction of cell death, HSCs were treated with capsaicin, a 
TRPV1 agonist, and no cytotoxic effect was observed (Figure 12C). 
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Figure 12. (A) Mouse HSCs were incubated with the specific receptor antagonists AM251 (1 µM), 
SR144528 (1 µM) or capsazepine (5 µM) for CB1, CB2 or TRPV1 receptors, respectively, 30 min prior 
to addition of NADA (25 µM) for 4 h. (B) HSCs isolated from mice lacking the CB1 and CB2 receptor 
(CB1-/-/CB2-/-) and from wild type mice were stimulated with 25 µM NADA for 4 h. (C) Mouse HSCs 
were stimulated with capsaicin or vehicle (-) for 8 h with the indicated concentrations. Cell death was 
analysed by LDH assay. *p<0.05 vs. NADA alone. 
 
4.2.6 NADA-induced cell death does not depend on membrane cholesterol 
Previous studies in primary HSCs as well as in other cell types have shown that AEA induces 
cell death through interaction with phospholipid bilayers via cholesterol-rich lipid rafts 
(Maccarrone & Finazzi-Agro, 2003; Siegmund et al., 2005b) (Yang, Liu, Zhang, Wu, & Tang). 
To test whether removing of cholesterol has cytoprotective effects in NADA-stimulated 
HSCs, the content of cholesterol in the cell membrane was reduced by incubating hepatic 
stellate cells with MCD (Siegmund et al., 2005b), a membrane cholesterol depletor, prior to 
stimulation with NADA or AEA. Accordingly, MCD completely inhibited necrosis induced by 
25 µM AEA but not by 25 µM NADA (Figure 13). This result indicates that NADA does not 
require interaction with membrane cholesterol for induction of cell death in HSCs. 
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Figure 13. Murine HSCs were incubated with the 
membrane cholesterol depletor MCD (1 mM) for 1 h 
and afterwards stimulated with 25 µM NADA or AEA for 
4 h. Cell death was analyzed by LDH assay. **p<0.001 
vs. NADA or AEA alone. 
 
4.2.7 NADA-induced necrosis is accompanied by an increase in intracellular 
reactive oxygen species (ROS) 
Previous studies showed that ROS formation is involved in AEA-induced cell death 
(Siegmund et al., 2005b). To anayse whether NADA stimulation promotes ROS formation, 
the generation of ROS in NADA-treated cells was determined. Comparable to AEA, NADA 
caused a marked and rapid increase of over 400 % in ROS formation compared to vehicle-
treated cells, which started one minute after stimulation at concentrations of 50 and 100 µM. 
Moreover, 25 µM NADA significantly doubled the ROS amount in the cells after four minutes 
of stimulation. There are no significant differences in ROS induction between the several 
NADA concentrations (Figure 14A). The generation of ROS induced by NADA did not differ 
from the ROS production induced by the corresponding concentrations of AEA (Figure 14B).  
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Figure 14. Activated rat HSCs were loaded with CM-H2DCFDA (5 µM) for 30 min and treated with 
100 µM NADA, AEA or vehicle. Reactive oxygen species formation was measured in a platereader in 
quadruplicates (A) or green fluorescence of CM-H2DCFDA was visualized on a single cell (B).  
 
Pretreatment with the antioxidants GSH and TROLOX significantly reduced NADA-mediated 
cell death from 51 % to 16 % and 22 %, respectively (Figure 15A). Moreover, antioxidants 
ameliorated NADA-induced cell death in HSCs as shown by decreased PI staining of the 
nuclei (Figure 15B). To provide further evidence for ROS as a key mediator of the cytotoxic 
effects of NADA, antioxidants in HSCs were depleted by BSO pretreatment resulting in a 
significant increase in NADA-induced cell death 2 h after stimulation (Figure 15C). These 
results suggest that antioxidants like GSH or TROLOX protect HSCs from NADA-induced 
cell death. 
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Figure 15. (A) Activated rat HSCs were preincubated with 4 mM GSH or 100 mM TROLOX and 
treated with NADA (25 µM for 4 h). Cell death was analysed by LDH assay (B). Cells were treated with 
either NADA (25 µM) plus GSH (4 mM), NADA (25 µM) alone or vehicle (-) for 4 h. Necrotic cell death 
is shown by red staining of the nuclei by PI (B). (C) After incubation with BSO for 1 h, the cells were 
stimulated with NADA (5 µM) for 4 h. Cell death was measured by LDH release. *p<0.05, **p<0.001 
vs. NADA alone.  
 
4.2.8   FAAH determines resistance to NADA-mediated cell death in 
hepatocytes 
The expression of catechol-O-methyltransferase (COMT) and fatty acid amid hydrolase 
(FAAH), which were shown to be able to degrade NADA, was investigated in hepatocytes 
and in HSCs. COMT-expression was not detected in both cell types. In contrast to HSCs and 
hepatocytes, HEK293 cells displayed strong expression of the COMT protein (Figure 16A). 
Furthermore, pharmacological blockade of COMT by OR-486, a specific COMT-inhibitor, 
showed no difference in response of HSCs to NADA (Figure 16B). Confirming earlier studies 
(Siegmund et al., 2006), primary hepatocytes express large amounts of FAAH in contrast to 
primary HSCs (Figure 16A). To investigate whether the different expression of FAAH is 
responsible for the different susceptibility of hepatocytes and HSCs towards NADA-induced 
cell death, hepatocytes were first preincubated with URB597, a strong and selective inhibitor 
of FAAH, and afterwards stimulated with 25 µM NADA. Blocking of FAAH increased NADA-
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mediated cell death by 40 % (Figure 16C). Accordingly, hepatocytes isolated from FAAH 
knockout mice also showed a higher susceptibility towards NADA-induced cell death with 28 
%, 46 % and 61 % of cell death after 10 µM, 25 µM and 50 µM, respectively (Figure 16D).  
 
 
Figure 16. (A) COMT and FAAH protein expression were analysed in rat HSCs and hepatocytes by 
western blotting.  (B) Hepatocytes were either pretreated with vehicle or OR-486 (10 µM) followed by 
NADA stimulation (25 µM) for 24 h. (C) Hepatocytes were incubated with URB597 (10 µM) or BSO 
(100 mM) for 1 h followed by NADA stimulation (25 µM) for 24 h. (D) Cell death in FAAH-/- 
hepatocytes after treatment with indicated NADA concentrations was determined by LDH release. 
*p<0.05 vs. vehicle. 
 
To further investigate the role of FAAH, rat HSCs were infected with an adenovirus 
expressing rat FAAH (AdFAAH), which leads to a strong overexpression of the enzyme 
(Figure 17A). AdFAAH decreased NADA-induced cell death (25 µM) from 55 % to 23 %, 
similarly to AEA-induced cell death (Figure 17B). In contrast, HSCs infected with the control 
virus expressing only GFP showed no difference in NADA-induced cell death. NADA is 
metabolised by FAAH to dopamine and arachidonic acid, a structurally similar 
polyunsaturated fatty acid. To exclude that these substances have cytotoxic effects, HSCs 
were incubated with 25 µM of each substance for 4 h. Neither arachidonic acid nor dopamine 
induced any detectable cell death whereas NADA induced cell death in over 50 % of the cells 
(Figure 17D). 
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Figure 17. (A) Expression of FAAH protein in HSCs infected with AdGFP or AdFAAH was determined 
by western blotting. (B, C). HSCs were infected with AdFAAH or AdGFP for 12 h and treated 24 h 
later with 25 µM NADA for 4 h. PI staining of the nuclei visualised necrosis (B) or LDH release into 
the media was measured (C). *p<0.05 vs. AdGFP. (D) Cells were treated with arachidonic acid (AA), 
dopamine or NADA with a concentration of 25 µM for 4 h. Cell death was determined by LDH release. 
*p<0.05 vs. vehicle. 
 
4.3 Definition of the cellular source of elevated 2-AG levels in the 
liver  
To address upregulated 2-AG levels in the injured liver, first the expression of the 
synthesising enzymes diacylglycerol lipase (DAGL) α and β as well as the degrading 
enzymes fatty acid amide hydrolase (FAAH) and monoacyl glycerol lipase (MGL) in whole 
liver tissue of sham-operated and bile duct ligated mice were examined. The cellular origin of 
increased 2-AG levels is unknown so far, therefore the expression of proteins involved in 
production and metabolism of 2-AG were further determined in different cell types of the liver. 
4.3.1 Elevated levels of 2-AG in the injured liver by increased synthesis and 
decreased degradation 
To investigate the expression levels of the synthesising and degrading proteins of 2-AG 
during liver injury, bile duct ligated or sham operated mice were sacrificed on day 7 or day 14 
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after surgery and mRNA levels of DAGLα and β as well as of FAAH and MGL were 
examined in whole liver tissue. As shown in Figure 18, the mRNA levels of the 2-AG 
producing enzyme DAGLα were significantly decreased in the injured liver. Interestingly, 
DAGLβ expression was four fold higher on day 14 after bile duct ligation compared to 
DAGLβ levels in sham operated mice. To check which synthesising enzyme is predominantly 
present in the liver, DAGLβ mRNA levels were compared to DAGLα expression in whole liver 
tissue. Compared to DAGLα, a 40 fold higher DAGLβ expression was found suggesting that 
DAGLβ is the main 2-AG-synthesising enzyme in the liver. Moreover, the intrahepatic mRNA 
expression of FAAH and MGL was significantly decreased seven and 14 days after surgery 
indicating that elevated expression of DAGLβ and reduced levels of the degrading enzymes 
of 2-AG are responsible for the upregulated 2-AG levels during fibrogenesis (Figure 18). 
 
Figure 18: mRNA expression of the 2-AG production enzymes DAGLα (A) and DAGLβ (B) as well as 
the degradation enzymes FAAH (C) and MGL (D) were examined by quantitative RT-PCR. Shown is 
fold of expression in sham-operated mice after normalization to 18s. **p<0.001, *p<0.05  vs. sham-
operated. (E) DAGLβ mRNA expression is shown as fold of DAGLα expression in whole liver tissue 
after normalization to 18s RNA. **p<0.001 vs. DAGLα expression. 
 
4.3.2 The non-parenchymal cells of the liver are able to synthesise 2-AG 
Since the cellular origin of 2-AG levels in the liver is unknown, DAGLα as well as DAGLβ 
mRNA expression in isolated primary liver cell populations were determined. A strong 
expression of DAGLα as well as DAGLβ was found in hepatic stellate cells, Kupffer cells and 
liver sinusoidal endothelial cells indicating that the non-parenchymal cells are the major 
source of 2-AG production in the liver (Figure 19). The strongest expression of DAGLα was 
Results  47 
found in LSECs with a 20-fold higher expression compared to hepatocytes. The mRNA levels 
of DAGLα found in HSCs and KCs were still 10-fold higher compared to the level in the 
parenchymal cells (Figure 19A). Much more pronounced were the differences in DAGLβ 
expression. The mRNA levels of DAGLβ were 60-times higher in HSCs and LSECs 
compared to the levels in hepatocytes. While KCs showed lower expression than HSCs or 
LSECs, the levels of DAGLβ mRNA were still significantly higher than in hepatocytes (Figure 
19B). 
To check which DAGL type represents the predominant 2-AG producing enzyme in the liver, 
DAGLα and β expression was compared. Indeed, a significant higher expression of DAGLβ 
was found in all cell types of the liver compared to DAGLα levels (Figure 19C) confirming the 
pivotal role of DAGLβ in 2-AG synthesis.  
 
 
 
 
Figure 19. Expression of DAGLα (A) and DAGLβ 
(B) was determined in primary murine 
hepatocytes, HSCs, LSECs and KCs (n= 3 
independent isolations) by quantitative real time 
PCR. Shown is fold of expression in hepatocytes 
after normalization to 18s. **p<0.001 vs. 
expression in hepatocytes. (C) DAGLβ mRNA 
expression is shown as fold of DAGLα expression 
in the respective cell type after normalization to 
18s RNA. **p<0.001 vs. DAGLα expression. 
 
 
4.3.3 FAAH is expressed in hepatocytes whereas MGL was found mainly in 
HSCs and LSECs 
Quantitative real time PCR revealed that FAAH mRNA was mainly expressed in hepatocytes 
whereas LSECs displayed a marginal expression of FAAH mRNA. HSCs and KCs showed 
no detectable amounts of FAAH mRNA levels (Figure 20A). The highest MGL mRNA levels 
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were found in LSECs, where a 130-fold higher expression was observed compared to the 
expression in hepatocytes. HSCs also express significantly higher levels of MGL than 
hepatocytes whereas the expression pattern does not differ between KCs and hepatocytes 
(Figure 20B).  
 
Figure 20. Expression of FAAH (A) and MGL (B) was determined in primary murine hepatocytes, 
HSCs, LSECs and KCs by quantitative real time PCR. Shown is fold of expression in hepatocytes 
after normalization to 18s RNA. **p<0.001 vs. expression in hepatocytes. 
 
4.4 Analysis of 2-AG-induced cell death in HSCs 
Recently, it was shown that 2-AG is able to induce cell death in HSCs but not in hepatocytes. 
The exact mechanism of 2-AG-induced HSC death is not clear so far. To answer the 
question if metabolites of 2-AG are at least in part responsible for the cytotoxic effect of 2-
AG, an alternative endocannabinoid metabolic degradation pathway was examined. In this 
pathway, 2-AG is converted via the enzyme COX-2 in prostaglandin glycerol ester (PG-GE)  
(Kozak et al., 2002; Kozak et al., 2004). COX-2 could display a possible link between 2-AG 
stimulation and cell death and may therefore be relevant for the development of 
hepatoprotective therapies. 
4.4.1 COX-2 is expressed in the non-parenchymal cells in the liver and highly 
upregulated in the injured liver 
To determine the expression of COX-2 during fibrogenesis, mRNA levels were determined in 
sham operated and bile duct ligated mice. COX-2 mRNA levels were more than ten-fold 
increased seven days after bile duct ligation. Moreover, there was a nearly 60-fold induction 
of COX-2 expression fourteen days after bile duct ligation demonstrating that liver injury 
induces COX-2 mRNA expression. Additionally, the cellular source of COX-2 in the liver was 
determined. There was a 7-fold higher expression level in HSCs compared to the expression 
levels in hepatocytes (Figure 21).  
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Figure 21. (A) Expression of COX-2 was 
examined in sham-operated and bile duct 
ligated mice on day 7 and on day 14 after 
BDL. Shown is fold of expression in 
sham-operated mice after normalization to 
18s mRNA(B) Expression of COX-2 was 
examined in primary hepatocytes and 
HSCs (n=3 independent isolations) by 
quantitative real time PCR. Shown is fold 
of expression in hepatocytes after 
normalization to 18s mRNA. **p<0.001 vs. 
expression in hepatocytes. 
 
 
4.4.2 PGD2-GE but not –F2α and –E2 induces cell death in HSCs  
It was recently shown that 2-AG is first metabolised by COX-2 to unstable PGH2-GE that 
afterwards acts as a substrate for PGD-, PGE- or PGF-synthases resulting in PGD2-GE, 
PGE2-GE or PGF2α-GE, respectively (Kozak et al., 2004). To check whether these possible 
metabolites of 2-AG were involved in 2-AG-induced cell death, primary HSCs were 
stimulated with different prostaglandin glycerol esters. Interestingly, only PGD2-GE showed 
significant cytotoxic effects on primary stellate cells (Figure 22 A). To exclude that these 
effects are a result of prostaglandin D2 (PGD2), the metabolite of arachidonic acid, the cells 
were stimulated with PGD2 with a concentration of 50 µM.  In this experiment, no significant 
induction of cell death by PGD2 was observed (Figure 22 B). The results suggest that PGD2-
GE and not other PG-GE or PGD2 are involved in 2-AG-mediated HSC apoptosis. 
 
 
 
Figure 22. (A) Mouse HSCs 
were treated with 50 µM 
PGD2-GE, PGE2-GE, 
PGF2α-GE or vehicle (-) (A) 
and with 50 µM PGD2, 
PGD2-GE or vehicle (-) (B) 
for 16 h. Cell death was 
determined by LDH assay. 
**p<0.001 vs. vehicle. 
 
 
Results  50 
4.4.3 2-AG is metabolised to PGD2-GE in HSCs, but not in hepatocytes 
To examine whether 2-AG is metabolized by COX-2 to PGH2-GE and further by PGD- 
synthase to PGD2-GE, HSCs as well as hepatocytes were stimulated with 2-AG or vehicle for 
16 h. Subsequently, the PGD2-GE content was measured. No difference was observed in the 
PGD2-GE level of treated and untreated hepatocytes. Nevertheless, there was a significant 
induction of PGD2-GE production in 2-AG-stimulated HSCs reaching 2000-fold higher PGD2-
GE levels compared to vehicle treated cells indicating that HSCs but not hepatocytes are 
able to produce PGD2-GE when stimulated with 2-AG (Figure 23). 
 
 
 
Figure 23. Serum-starved primary 
hepatocytes and HSCs were treated with 
50 µM 2-AG or vehicle for 16 h. PGD2-GE 
concentration was measured by PGD2-
MOX EIA. **p<0.001 vs. hepatocytes. 
 
 
4.4.4 PGD2-GE induces cell death in HSCs as well as in hepatocytes 
To further analyse, whether differential expression of the alternative endocannabinoid 
degradation pathway by COX-2 contributes to the different susceptibility of HSCs and 
hepatocytes towards 2-AG, the cells were stimulated with either 50 µM 2-AG or PGD2-GE. 
Indeed, stimulation with PGD2-GE leads to considerable induction of cell death in HSCs as 
well as in hepatocytes. No cytotoxic effects were observed by stimulating hepatocytes with 
the adequate concentration of 2-AG suggesting that the metabolism of 2-AG to PGD2-GE 
through COX-2 contributes to the apoptotic effect of 2-AG (Figure 24). 
 
 
 
Figure 24. Serum-starved primary mouse 
hepatocytes and HSCs were treated either with 
50 µM PGD2-GE, 50 µM 2-AG or vehicle (-) for 
16 h. Cell death was measured by the release of 
LDH into the media. **p<0.001 vs. hepatocytes. 
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4.4.5 PGD2-GE induces apoptotic cell death in HSCs 
To further characterise PGD2-GE-induced cell death, caspase 3- and PARP-cleavage, two 
hallmarks of apoptotic cell death, were investigated. PGD2-GE-treatment showed  caspase 3- 
and PARP cleavage starting 16 h after stimulation (Figure 25) suggesting apoptotic cell 
death induced by PGD2-GE. 
 
Figure 25 A, B. Primary HSCs were treated with PGD2-GE (50 µM) or 2-AG (50 µM) as a positive 
control for the indicated times. Western blotting was performed with antibodies directed against 
cleaved caspase 3, cleaved PARP and β-actin.  
 
4.4.6 PGD2-GE-induced cell death is membrane cholesterol independent 
It was previously shown that membrane cholesterol depletion prevents HSCs from 2-AG-
induced cell death (Siegmund et al., 2007). HSCs were incubated with the membrane 
cholesterol depletor MCD and afterwards stimulated with either 2-AG or PGD2-GE. Although 
preincubation of MCD in 2-AG-treated cells displayed a strong regression in cell death 
(Figure 26A), no decrease in cytotoxicity was observed in PGD2-GE treated cells (Figure 
26B). Thus, cholesterol seems not to be involved in PGD2-GE-induced apoptosis. 
 
Figure 26 A, B. Primary HSCs were preincubated with the membrane cholesterol depletory MCD (1 
mM) 1 h before addition of 2-AG (25 µM) (A) or PGD2-GE (50 µM) (B) for 16 h. Cell death was 
assessed by LDH assay. 
 
 
Discussion  52 
5 DISCUSSION 
Liver fibrosis represents a wound healing response to a variety of chronic injurious stimuli 
including constant drug or alcohol abuse, viral infections or metabolic disorders (Bataller et 
al., 2005). This perpetuating wound healing reaction is characterised by excessive 
accumulation of extracellular matrix (ECM) proteins, which replace the lost parenchyma 
leading to loss of liver function (Friedman, 2008a). Liver cirrhosis, the end stage of fibrosis, 
represents a major health problem with high mortality worldwide (Lotersztajn, Julien, 
Teixeira-Clerc, Grenard, & Mallat, 2005). HSCs are mainly responsible for the increased 
synthesis and deposition of ECM in the liver. Following liver injury, HSCs activate and 
transdifferentiate into myofibroblast-like cells expressing large amounts of ECM.  
After acute damage of liver cells, ECM proteins are degraded and liver function is recovered. 
If the hepatic injury becomes chronic, the reconstitution of liver function is not achieved 
(Friedman, 2008a).  
Following removal of the causative agent like eradication of hepatitis C virus infection or 
cessation of alcohol abuse, liver fibrosis can reverse and result in a complete normal hepatic 
architecture (Bataller et al., 2005; Siegmund et al., 2005a). Therefore, treatment of the 
underlying disease is of course the most effective approach. If this is not possible, additional 
therapeutic options are required. Selective induction of cell death in hepatic stellate cells, the 
main fibrogenic cell type in the liver, has been linked to the resolution of fibrosis (Iredale et 
al., 1998). Recently it was shown, that endocannabinoids are able to induce specifically cell 
death in HSCs but not in hepatocytes making these substrates good candidates for the 
treatment of liver fibrosis (Siegmund et al., 2007; Siegmund et al., 2005b).  
5.1 Cultivation of hepatic stellate cells 
Hepatic stellate cells were first described by Kupffer in the 19th century. They represent one 
third of non-parenchymal cells and 8 % of the total cells in the liver. In their quiescent state, 
HSCs function as the major vitamin A storing cells in the body containing over 80 % of total 
vitamin A (Friedman, 2008b). During liver injury, HSCs become activated and 
transdifferentiate into a myofibroblast-like phenotype, which is known to be the most 
dominant pathway in fibrogenesis (Enzan et al., 1997; Schmitt-Graff, Desmouliere, & 
Gabbiani, 1994). Due to its pivotal role in liver injury, the attention regarding the treatment of 
liver fibrosis turned to the stellate cell. The inhibition of activation or the specific induction of 
death in HSCs could represent a tool for the treatment of liver fibrosis. 
The development of HSC isolation and cultivation represent a major advance to explore the 
cell function in healthy and injured liver. The isolation is based on in situ digestion following 
density gradient centrifugation, which is again based on the intracellular vitamin A content of 
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the cells. During the first two days, the cells display a high amount of cytoplasmatic lipid 
droplets containing retinoids, mostly vitamin A. The autofluorescence of vitamin A under UV-
light is used to discriminate HCSs and other resident liver cells that allows the determination 
of the cell culture purity (Friedman et al., 1985; Volk & Popper, 1950).   
After two days of cultivation, the cells act like in the injured liver: they activate and 
transdifferentiate into myofibroblast-like cells with bundles of numerous microfilaments 
(Schmitt-Graff et al., 1994). Moreover, they start to proliferate like their counterparts in vivo. 
Therefore, cultivation of primary HSCs represent a good tool for the study of liver fibrosis.  
Activation of HSCs in culture can be shown by α smooth muscle actin (α-SMA) expression. 
α-SMA is localised within the microfilament bundles of myofibroblasts or fibroblasts and is 
essential for the contractility of the cells (Schmitt-Graff et al., 1991; Serini et al., 1999). 
Induction of α-SMA is the most reliable marker of stellate cell activation, due to its absence in 
other resident liver cells (Bataller et al., 2005; Rockey, Boyles, Gabbiani, & Friedman, 1992). 
Moreover, α-SMA staining is increasingly used as an indicator for hepatic fibrosis in patients 
even before ECM accumulates (Gawrieh et al., 2005; Russo et al., 2005).    
Analysis of inhibition of activation and induction of cell death in HSCs disclose new prospects 
for patients with end-stage disease in the future. 
5.2 Investigation of the effects of noladin ether, virodhamine and 
NADA on liver cells 
Up to now it is known that the hepatic 2-arachidonoyl glycerol (2-AG) and anandamide (AEA) 
levels as well as the expression levels of their receptors are strongly upregulated in hepatic 
injury and fibrogenesis (Biswas et al., 2003; Julien et al., 2005; Siegmund et al., 2007; 
Siegmund et al., 2005b). Furthermore, it was shown that 2-AG induces apoptotic cell death 
specifically in HSCs but not in hepatocytes (Siegmund et al., 2007). AEA, which belongs to 
the group of N-acyl-ethanolamines, was shown to induce necrotic cell death in HSCs 
whereas no cytotoxic effect was shown in the parenchymal cells of the liver (Siegmund et al., 
2005b).  
In this thesis it is reported the first time that the three recently discovered enocannabinoids, 
virodhamine, noladin ether and NADA specifically induce necrotic cell death in hepatic 
stellate cells in a dose-dependent manner. In contrast, hepatocytes are resistant to 
virodhamine-, noladin ether- as well as to NADA-mediated cell death. As mentioned above, 
the biosynthetic pathways of virodhamine and noladin ether are not investigated so far. 
Interestingly, in this study it was shown that the rate-limiting production enzyme of NADA, 
tyrosine hydroxylase, is expressed in normal as well as in injured liver. Western blotting 
revealed a strong expression in primary hepatocytes but not in activated primary HSCs, 
indicating a selective role of hepatocytes in NADA production in the liver. By this finding, the 
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study of the effects of this endocannabinoid achieves in vivo relevance. The focus shifted to 
further investigations of NADA. Moreover, virodhamine and noladin ether belong to the group 
of ethanolamides and monoglycerols, respectively, that were both already examined in 
hepatic cells (Piomelli, 2003). NADA belongs to the N-acyl-dopamines, a novel group of 
endocannabinoids, which has not been investigated in the liver so far (Bisogno et al., 2000). 
The fact that the cytotoxic potency of NADA occurs in the short time period of 2 h after 
stimulation with 25 µM led to the suggestion that cell death induced by NADA is necrotic. 
Since endocannabinoids display a volatile appearance due to their production on demand 
and fast degradation (Di Marzo et al., 2004), the rapid induction of cell death shown here in 
cell culture experiments assumed a possible cytotoxic effect on HSCs in vivo. It has been 
shown that AEA induces cell death with concentrations of 2-20 µM, depending on the cell 
type (Contassot, Tenan, Schnuriger, Pelte, & Dietrich, 2004a; Contassot et al., 2004b; 
Giuliano et al., 2006; Saunders et al., 2009). NADA concentrations may also reach levels 
comparable to AEA and rapidly induce cell death in HSCs. Therefore, the mainly used 
concentration of 25 µM NADA in this thesis can be considered to be in the physiological 
range of NADA levels in vivo. 
 Due to the fact that NADA-induced cell death in other cell types is apoptotic and occurs 
much later, the necrotic character of NADA-mediated cell death was examined in the present 
study. To further confirm that the form of cell death induced by NADA was necrotic, cells 
were treated with propidium iodide, a marker for necrosis, which results in a strong PI 
staining of the nuclei of NADA-treated cells. As expected, caspase inhibition with a specific 
caspase-inhibitor (Z-VAD-FMK) decreased TNFα-induced HSC apoptosis, but not NADA-
induced death, prefiguring caspase 3-independent necrosis. 
Another important question to answer was the impact of nanomolar concentrations of NADA 
on activated primary HSCs. The results obtained from the wound healing assay demonstrate 
a remarkable inhibitory effect on proliferation and migration. To analyze the influence of 
NADA to HSC proliferation in more detail, the phosphorylation of ERK was determined. In a 
recent study it was shown that the activation of this kinase displays pro-proliferative and anti-
fibrotic effects in HSCs (Teixeira-Clerc et al., 2006). In the present thesis, a remarkable 
inhibition of ERK phosphorylation was observed by exposure of the cells to NADA. Moreover, 
a lower expression of α-SMA was detected after daily treatment of freshly isolated HSCs with 
1000 nM of NADA, indicating that NADA is also able to decelerate HSCs activation, which in 
contrast was not achieved by comparable concentrations of AEA. These findings represent 
another aspect of the anti-fibrotic properties of NADA in the liver. 
NADA was recently identified as an endogenous ligand for the transient receptor potential 
vanilloid type 1 (TRPV1) channel due to its vanillyl-amine moiety (Bisogno et al., 2000; De 
Petrocellis, Bisogno, Davis, Pertwee, & Di Marzo, 2000; Walpole et al., 1993). Moreover, 
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recent studies have demonstrated that TRPV1 plays a pivotal role in NADA-induced cell 
death in a neuron-like cell population by generation of reactive oxygen species (ROS) 
(Davies et al.). In contrast to the findings of Davies and colleagues, the results obtained from 
the co-stimulatory experiments with NADA and capsazepine, a specific inhibitor of TRPV1, 
did not show any difference in the susceptibility of NADA-induced cell death. When the cells 
were exposed to a specific agonist of TRPV1, capsaicin, no cell death could be observed, 
which argues against an involvement of this receptor in NADA-induced cell death. Moreover, 
there was no evidence for an involvement of CB1 receptors in this process, although the 
binding affinity of NADA to CB1 receptors is even higher than the affinity of AEA (Bisogno et 
al., 2000). Additionally, the involvement of the CB2 receptor, to which NADA shows low 
affinity, could also be ruled out. Considering that NADA does not display any dopamine 
receptor activity, although NADA possesses a dopamine moiety (Bisogno et al., 2000), the 
involvement of these receptors was not investigated. Since all three receptors investigated in 
this study are expressed on HSCs (Siegmund et al., 2005b), but were shown not to be 
involved, NADA induced cell death independently of these receptors. Previously it was 
shown that AEA-mediated cell death requires the presence of membrane cholesterol 
(Siegmund et al., 2005b). An alternative mechanism might be that NADA, like AEA, acts 
through membrane cholesterol to induce cell death. This would explain at least in part the 
different susceptibility of HSCs and hepatocytes, since hepatocytes have significantly less 
cholesterol in their plasma membrane (Siegmund et al., 2005b). However, the fact that 
preincubation with the membrane cholesterol depletor MCD did not prevent HSCs from cell 
death indicated that cholesterol-rich lipid rafts are not involved. However, the exact signal 
transduction from cellular uptake to initiation of death induced by NADA remains to be 
elucidated. 
NADA stimulation induced a rapid induction of ROS in similar ranges as AEA. High amounts 
of rapidly generated ROS are known to lead to damage of intracellular macromolecules thus 
initiating necrosis (Raffray & Cohen, 1997). In the present study, treatment of HSCs with 
antioxidants (GSH, TROLOX) blocked the induction of cell death. In line with that, after the 
depletion of antioxidants, 10 µM NADA was sufficient to significantly induce cell death 
suggesting a pivotal role of ROS generation in the process. 
As mentioned above, a stable expression of tyrosine hydroxylase (TH), the rate limiting 
NADA-generating enzyme, was found in hepatocytes, but not in HSCs, indicating that 
hepatocytes possess the capability for NADA production. Since NADA-mediated death of 
HSCs was triggered by rapid induction of noxious ROS production and could be ameliorated 
by incubation of the cells with antioxidants, it was first checked whether depletion of GSH in 
hepatocytes could render susceptibility toward NADA-mediated death. Indeed, hepatocytes 
resistance toward NADA-induced cell death was due to the effective antioxidant defence 
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mechanism of high GSH expression. Moreover, additional factors that may confer resistance 
against NADA-mediated cell death were investigated. Hu and colleagues revealed in 2009 
that NADA represents a good substrate for catechol-O-methyl transferase (COMT) (Hu et al., 
2009). NADA is converted by COMT to its less potent 3-O-methyl derivative. However, 
COMT expression in hepatocytes as well as in HSCs were under the detection level in the 
experiment discussed here, although there was a strong expression in HEK293 cells. 
Consequently, this degradation pathway did not contribute to NADA resistance observed in 
hepatocytes, since selective inhibition of COMT by the specific inhibitor OR-486 did not 
rescue hepatocytes from the cytotoxic effects of NADA.  
Another degradation pathway of NADA is its hydrolysation by fatty acid amide hydrolase 
(FAAH) into arachidonic acid and dopamine (Hu et al., 2009; Huang et al., 2002). FAAH has 
initially been identified as the primary degradation enzyme for AEA (Cravatt et al., 1996). It 
has been shown that NADA is also metabolised by FAAH but five-fold slower than AEA due 
to the higher metabolic stability of NADA regarding to the dopamine derivative (Hu et al., 
2009). Consistent with previous studies, FAAH is highly expressed in hepatocytes but not in 
HSCs (Siegmund et al., 2006). Treatment with URB597, a specific inhibitor of FAAH, 
rendered hepatocytes susceptibility to NADA-induced cell death. Additionally, hepatocytes 
isolated from FAAH -/- mice are sensitised to NADA-mediated death. To further elucidate 
these findings, FAAH was overexpressed in HSCs using a FAAH-expressing adenovirus 
resulting in resistance against NADA. The results of these studies underline the pivotal role 
for FAAH in mediating resistance of the liver parenchyma to the cytotoxic effects of NADA. 
Similar results were obtained in recent studies, where FAAH was shown to play a crucial role 
in the resistance of hepatocytes against AEA-induced cell death (Siegmund et al., 2006).  
In conclusion, NADA mediates cell death specifically in HSCs due to increased generation 
ROS (Figure 27). NADA does not induce cell death in hepatocytes due to their high levels of 
antioxidants and FAAH. FAAH was also shown to be a putative synthesising enzyme for 
NADA (Hu et al., 2009), but since FAAH primarily conferred resistance against NADA-
induced cell death, FAAH displays rather a pivotal role in NADA degradation in these cells 
than in synthesis. 
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Figure 27. Scheme of the proposed NADA-induced cell death. Hepatocytes produce N-arachidonoyl 
dopamine (NADA) catalysed by tyrosine hydroxylase (TH). After release, NADA inhibit activation of 
hepatic stellate cells (HSCs) by a yet unknown mechanism. Furthermore, NADA induces necrotic cell 
death in HSCs by a strong induction of reactive oxygen species (ROS) generation. Hepatocytes are 
protected against NADA-mediated cell death due to high levels of antioxidants (GSH) and strong 
expression of fatty acid amide hydrolase (FAAH), which is able to degrade NADA. 
 
The selective expression of effective defence systems (antioxidants, FAAH) and the selective 
expression of the rate-limiting NADA producing enzyme TH in hepatocytes as well as the 
selective induction of cell death in HSCs shown by the present analyses proposes NADA as 
a novel anti-fibrotic endogenous agent. 
5.3 Definition of the cellular source of elevated 2-AG levels in the 
liver 
2-arachidonoyl glycerol (2-AG) is an endogenous arachidonic acid derivative released on 
demand from membrane precursors (Piomelli, 2003). In 1995, 2-AG was distributed to the 
group of endocannabinoids. Many of the effects of 2-AG are mediated by the cannabinoid 
receptors CB1 and CB2 (Mechoulam et al., 1995). The normal, healthy liver contains only 
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small amounts of 2-AG. However, liver injury caused by ischemia/reperfusion triggers 
significantly augmented 2-AG levels. Furthermore, ethanol feeding in mice led to an 
upregulation in hepatic 2-AG levels (Batkai et al., 2007; Jeong et al., 2008). A significant 
increase in 2-AG levels was also found in two well-established mouse models of liver injury 
and fibrosis. For the induction of hepatic injury and fibrogenesis, mice underwent either 
ligation of the common bile duct leading to cholestatic liver disease or were treated with CCl4 
causing toxic liver damage. In both models an approximately three-fold elevation of 2-AG 
was observed (Siegmund et al., 2007). Taken together, 2-AG is strongly upregulated in 
hepatic injury and fibrogenesis. Up to now, it is not known whether an increase in the 
synthesis or a decline in the expression of degradation enzymes is responsible for this effect. 
2-AG is produced via the hydrolysis of diacylglycerol (DAG) with arachidonate, which is 
catalysed by one of two highly related DAG lipases (DAGLα and β), depending on the cell 
type (Gao et al.). To examine the role of 2-AG synthesis in liver fibrogenesis, the expression 
of DAGLα and β were examined in bile duct ligated mice. The expression of DAGLα was 
clearly decreased, excluding that this lipase is responsible for elevated 2-AG levels found in 
the injured liver. Although there was no significant induction of DAGLβ expression seven 
days after surgery, the results showed clearly a five-fold significant increase in DAGLβ 
mRNA levels on day 14. In whole liver tissue, 40-fold higher levels of DAGLβ compared to 
DAGLα were observed. A previous study showed that DAGLα is expressed in the liver and 
there is a 60 % reduction in 2-AG levels in DAGLα-/- mice. Nevertheless, loss of DAGLβ 
results in an almost 90 % decrease of 2-AG (Gao et al.) suggesting that DAGLβ is the main 
2-AG producing enzyme in the liver. On the cellular level, these findings were confirmed 
since the amount of DAGLβ mRNA is up to 100-fold higher than the amount of DAGLα in all 
examined liver cells. These data and the data published by Gao et al. prefigure DAGLβ 
rather than DAGLα as the main 2-AG-producing enzyme in the liver.  
 The late onset of DAGLβ expression as the dominant synthesising machinery in the liver 
may be at least in part responsible for the elevated 2-AG levels in the injured liver. The fact 
that an increased 2-AG content could already be detected three days after bile duct ligation 
(Siegmund et al., 2007) implies the involvement of other mechanisms in the upregulation of 
2-AG levels during liver injury and fibrogenesis. Therefore, the focus of the present study 
switched to the investigation of changes in 2-AG degradation pathways. 
After its cellular uptake, 2-AG is rapidly degraded by intracellular hydrolysis catalysed by the 
serine hydrolase monoacylglycerol lipase (MGL) (Bisogno, Ligresti, & Di Marzo, 2005; Dinh 
et al., 2004). Moreover, it was shown, that FAAH is able to degrade 2-AG in vitro (Muccioli). 
In the bile duct ligated mice analysed here, a significant decline in FAAH as well as in MGL 
levels were observed seven days after surgery. This reduction in the metabolism of 2-AG 
possibly explains its upregulation in the early state of liver damage. Since it was shown that 
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FAAH-/- mice showed unchanged tissue levels of 2-AG (Muccioli) (Patel et al., 2005), MGL 
rather than FAAH seems to be the responsible enzyme for increased 2-AG levels.  
Up to now, no data exists on the contribution of different cell types in the liver to the 
production and metabolism of 2-AG. To investigate which cells are mainly involved in the 
production of 2-AG, the expression levels of DAGLα as well as DAGLβ were examined in 
hepatocytes and non-parenchymal cells. In contrast to the low DAG lipase levels in 
hepatocytes, a strong expression of DAGLα as well as β in the non-parenchymal cells of the 
liver was observed suggesting that these cells are the major source of 2-AG production. In 
recent studies, it was increasingly recognized that substances produced from non-
parenchymal cells regulate many functions of the liver conducted by hepatocytes. It is 
possible that endocannabinoids are also produced by this cell fraction and interact with the 
parenchyma. Lately it has been shown that 2-AG produced in HSCs mediated an induction of 
CB1 receptors on hepatocytes, which indicates a paracrine signalling mechanism between 
these liver cell populations (Jeong et al., 2008).  
The results presented here demonstrate that LSECs and to a lesser extend HSCs are the 
main DAGLβ expressing cells in the liver. This is partly consistent with a previous study, 
which has shown that HSCs are the main source for increased hepatic 2-AG levels after 
ethanol feeding in mice. Indeed, no expression of DAGLβ and no upregulated 2-AG levels 
were found in hepatocytes (Jeong et al., 2008). Nevertheless, other cell types in the liver, like 
LSECs were not investigated so far. LSECs are responsible for the secretion of various 
cytokines and due to the fact that they possess the synthesising machinery of 2-AG, they 
appear to be able to produce and secrete 2-AG for autocrine or paracrine signalling in the 
liver. This corresponds to the finding that LSECs possess CB1 as well as CB2 receptors, 
which are both receptors for 2-AG (Batkai et al., 2001; Batkai et al., 2007). In this study, it is 
shown the first time, that LSECs crucially contribute to 2-AG production and may be mainly 
responsible for the upregulation of 2-AG levels in the injured and fibrotic liver. Interestingly, 
LSECs and HSCs express the highest levels of MGL in the liver, leading to the conclusion 
that these cell types possess the production and the degradation machinery for 2-AG.  
FAAH is mainly expressed in hepatocytes, but only marginally in the non-parenchymal cells. 
This finding is in good agreement with similar results from previous studies, where FAAH 
expression levels were examined in HSCs and hepatocytes. However, in the study at hand it 
was shown that other non-parenchymal cell types do not express FAAH. Thus, hepatocytes 
are able to degrade endocannabinoids such as 2-AG although they lack the capability of their 
synthesis. 
In conclusion, 2-AG in the liver is mainly produced and degraded by LSECs and HSCs. 
Elevated 2-AG levels occurring during fibrogenesis are rather driven by decreased 
degradation than by upregulation of production. The data further point towards LSECs and 
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HSCs rather than to other cell types as being the most important hepatic cell populations for 
2-AG metabolism during liver injury and fibrogenesis.  
5.4 Analysis of 2-AG-induced cell death in HSCs 
After identification of the cellular source and the enzymes responsible for 2-AG upregulation, 
the focus shifted to the analysis of the potential, anti-fibrogenic properties of 2-AG. 2-AG 
induces cell death in HSCs, the main fibrogenic cell type in the liver, which is accompanied 
by a dramatic increase in the generation of mitochondrial reactive oxygen species (ROS). In 
contrast to HSCs, hepatocytes were completely resistant to 2-AG-induced cell death. 
However, the reason for the different susceptibility and the exact mechanism underlying this 
effect is unclear so far (Siegmund et al., 2007).  
The cytotoxic effects of 2-AG could not be explained by activation of the known receptors or 
by metabolism via its degradation enzymes MGL and FAAH. Inhibition of the receptors or 
MGL did neither alter the sensitivity of 2-AG induced cell death in HSCs nor in hepatocytes 
(Siegmund et al., 2007). Furthermore, due to the lack of FAAH expression in HSCs, the 
involvement of metabolites of FAAH was also excluded (Siegmund et al., 2006).  
The presence of a arachidonoyl moiety in the structure of 2-AG suggests that it is able to 
serve as a substrate for metabolism by other enzymes beside FAAH and MGL (Kozak et al., 
2004). Indeed, a few years ago COX-2 was shown to metabolise AEA and 2-AG to 
prostamides and prostaglandin glycerol esters (PG-GE), respectively (Kozak et al., 2002). 
However, in liver fibrogenesis the effects of COX-2 are discussed controversially and a 
definitive role for COX-2 has not been elucidated so far (Yu et al., 2008). It is known that 
COX-2 is marginally expressed in healthy liver. In response to inflammation, COX-2 is highly 
inducible by inflammatory cytokines and has been reported to be increased in several types 
of liver injury such as chronic hepatitis or cirrhosis (Jeong et al.). COX-2 inhibitors were 
shown to decrease α-SMA expression in HSCs (Cheng et al., 2002) and were able to reduce 
CCl4-induced liver fibrosis in mice (Horrillo et al., 2007). In contrast, COX-2 displayed hepato-
protective activities in models of toxic liver injury in mice and in CCL4-induced liver fibrosis in 
rats (Hui et al., 2006; Reilly et al., 2001). 
To analyse the expression pattern of COX-2 under fibrogenic conditions in an animal model, 
livers of sham operated and bile duct ligated mice were investigated for COX-2 expression. A 
significant increase of 13-fold or more than 60-fold was found seven days and fourteen days 
after surgery, respectively. It seems that the expression of COX-2 is strongly upregulated in 
the early states of hepatic inflammation and injury. The cells in the liver that are typically 
involved in the inflammatory response are KCs, the resident macrophages in the liver. 
Previously it was shown that KCs represent the primary source for COX-2 in alcoholic liver 
disease (Nanji et al., 1997). In contrast, hepatocytes in primary culture as well as in vivo are 
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not able to express high amounts of COX-2 even after onset of inflammation (Martin-Sanz, 
Mayoral, Casado, & Bosca). This is consistent with the results of this study, since 
hepatocytes only marginally expressed COX-2. Interestingly, HSCs showed seven-fold 
higher levels of COX-2 compared to hepatocytes. Julien and colleagues showed that 
increasing levels of COX-2 have growth-inhibitory effects on HSCs, which were reduced by 
specific COX-2 inhibitors. In their study, the exogenous cannabinoid THC was responsible 
for the upregulation of COX-2 (Julien et al., 2005). Moreover, cannabinoids are also able to 
induce COX-2 expression in neuroglioma and lung cancer cells (Bifulco, Laezza, Pisanti, & 
Gazzerro, 2006). If cannabinoid-induced upregulation of COX-2 leads to growth arrest in 
HSCs, endocannabinoids such as 2-AG represent a possible antifibrotic tool. Indeed, it is 
known that 2-AG also evokes growth arrest by a yet unidentified mechanism (Jacobsson, 
Wallin, & Fowler, 2001). 
In the injured liver, paralleling the overexpression of COX-2, 2-AG is also strongly 
upregulated (Siegmund et al., 2007). The question rose whether COX-2 plays a noteworthy 
role in 2-AG-induced cell death. 2009, it was shown that the endocannabinoid anandamide 
selectively induces cell death in keratinocytes due to elevated COX-2 expression and the 
resulting metabolism of AEA to cytotoxic prostaglandin ethanol amides. This work reflects the 
significance of endocannabinoid metabolic products in the initiation of cell death (Van Dross, 
2009). COX-2 was shown to metabolise 2-AG more efficiently than AEA (Kozak et al., 2004). 
The cytotoxic effects of 2-AG could correlate with the catalytic activity of COX-2, which 
metabolises this endocannabinoid to prostaglandin glycerol esters. 
To examine, whether PG-GEs have any effects on HSCs and hepatocytes, primary cells 
were treated with various PG-GE to determine the contribution of each to induce cell death. 
Interestingly, only prostaglandin D2 glycerol ester (PGD2-GE) was found to have cytotoxic 
effects. It is known that 2-AG induces apoptotic cell death in HSCs but not in hepatocytes 
(Siegmund et al., 2007). After oxygenation of 2-AG to PGD2-GE, cell type specific toxicity is 
not present anymore and the COX-2 metabolite induced apoptosis in HSCs as well as in 
hepatocytes via a caspase-3- and PARP-dependent pathway.  
Less is known about the biosynthesis of PG-GE in vivo. In a previous study it was shown that 
COX-2 converted exogenous 2-AG to PGH2-GE. PGD synthase converted the H2 derivative 
to PGD2-GE as the final glycerol ester product in a macrophage cell line (Kozak et al., 2000). 
Indeed, HSCs were able to metabolise the endocannabinoid 2-AG to PGD2-GE, in contrast 
to hepatocytes, which failed to produce prostaglandins. These findings represent a possible 
explanation for the resistance of hepatocytes to 2-AG-mediated cell death due to the lack of 
COX-2 expression. However, less is known about PGD2-GE and the role of this metabolite in 
2-AG-induced apoptosis has to be further characterised.  
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It was previously shown that PGD2-GE could spontaneously be converted to its 
prostaglandin counterpart (PGD2). PGD2 inhibits cell proliferation and induces apoptosis in 
various cell types including non-small cell lung carcinoma (Wang & Mak), leukaemia cells 
(Azuma, Watanabe, Date, Daito, & Ohura, 2004) and colon cancer cells (Yoshida et al., 
1998). Interestingly, in this thesis, rather PGD2-GE than PGD2 is responsible for the cytotoxic 
effect of 2-AG in HSCs.  
Up to now, limited data is available regarding the metabolism of endocannabinoids as a 
source of novel lipid mediators. COX-2 activity was mainly found in the central nervous 
system, inflammatory cells and also in liver cells paralleling the distribution of cannabinoid 
receptors (Kozak et al., 2000). Nevertheless, the connection between the endocannabinoid 
system and COX-2 has slowly been uncovered. The experimental results in this study 
suggest that part of the cytotoxic effects of 2-AG in HSCs is attributed to high COX-2 
expression and conversion of 2-AG by COX-2 to cytotoxic PG-D2-GE (Figure 28). 
 
 
Figure 28. Scheme of proposed 2-arachidonoyl glycerol (2-AG) death signalling. 2-AG bind to 
unknown structures in cholesterol rich lipid rafts. Inside the cell, 2-AG is metabolised to prostaglandin 
D2 glycerol ester (PGD2-GE) catalysed by cyclooxygenase-2 (COX-2). PGD2-GE possibly 
upregulates the generation of reactive oxygen species (ROS) and induces caspase-3-dependent 
apoptotic cell death in hepatic stellate cells (HSCs). 
 
In this study, the advantage of COX-2 catalytic activity was explored. The results showed 
that the metabolites of 2-AG were toxic specifically in HSCs, which express high amounts of 
COX-2. Since COX-2 is expressed specifically in HSCs and it is possible to induce an 
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upregulation of COX-2 by endocannabinoids, 2-AG may be useful for the treatment of liver 
fibrosis. The data reported in this study suggest that COX-2 expression provides a supply of 
bioactive lipids-protect against liver injury.  
5.5 Conclusion and future directions 
The results presented in this work provide new insights in the role of the endocannabinoid 
system in the liver. Modulating this system seems to be a promising target for the treatment 
of hepatic injury.  
HSCs are highly sensitive to endocannabinoid-induced cell death. In recent studies it was 
shown that 2-AG and AEA are able to induce specifically cell death in HSCs (Siegmund et 
al., 2007; Siegmund et al., 2005b). However, their susceptibility to enzymatic hydrolysis 
reduces the efficiency and more stable endocannabinoids may serve better for a model of 
drug development. In addition, due to their fast degradation, a rapid induction of cell death is 
necessary for using these lipid mediators as an approach for antifibrotic therapy. This thesis 
showed that NADA-induced cell death occurred very fast. In contrast to 2-AG and AEA, 
NADA is much more stable and is degraded 5-times slower by FAAH than AEA (Hu et al., 
2009). Thus, NADA has the conditions to function as an antifibrotic tool.  
Moreover, hepatocytes are shown to be able to produce NADA in the injured liver. The 
hypothesis is that after its release, NADA can act on HSCs and inhibit activation or –in higher 
doses- induce cell death. Unquestionably, more work is necessary to examine the exact 
mechanism how NADA participate in the pathophysiology of liver fibrosis. However, the 
findings of this work provide new insights of the possible role of NADA as an antifibrotic tool. 
In future studies, the effects of NADA on other hepatic cell types should be investigated. Are 
Kupffer and LSEC cells protected against NADA-induced cell death?  
Another question rose: Does NADA also have physiological functions in the healthy liver? 
Indeed, the NADA synthesising enzyme TH is expressed in normal liver. However, further 
information is required to fully understand the role of NADA in the healthy as well as the 
injured liver.  
It is known that 2-AG levels are strongly upregulated during hepatic fibrogenesis (Siegmund 
et al., 2007). This thesis showed that the expression of the 2-AG-synthesising enzyme 
DAGLβ is elevated in liver injury whereas the levels of MGL, which is responsible for 2-AG 
degradation, are significantly decreased. These findings can certainly offer new therapeutic 
perspectives: modulation of DAGLβ as well as MGL levels can be used to keep 2-AG levels 
upregulated and decelerate fibrogenesis by its antifibrotic effects. 
One believed antifibrotic effect of 2-AG is cell death induction specifically in HSCs (Siegmund 
et al., 2007). The results of this thesis suggested that the cytotoxic effect of 2-AG is due to its 
conversion to PGD2-GE by COX-2. This finding provides new insights in the understanding of 
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the molecular mechanisms of 2-AG-induced cell death. Moreover, the results of this work 
shifted the focus from 2-AG to PGD2-GE as an antifibrotic substance. Needless to say, 
further studies are required to investigate the role of COX-2 in 2-AG-induced cell death.  
In this work, NADA, 2-AG and also PGD2-GE as antifibrotic agents are effective in cultures of 
activated HSCs. In future studies, the next step has to be the investigation in experimental 
models of liver fibrosis in vivo. The findings of endocannabinoid treatment in liver-injured 
animals may have clinical relevance in the development of antifibrotic therapies.  
Another important problem to solve will be the specific targeting of activated HSCs. The 
agent should not bind to myofibroblasts in other tissues or to quiescent HSCs. Moreover, it 
has to reach the regions with active fibrogenesis. Future work should be focus on novel 
carriers which bind specifically to activated HSCs. like to the collagen type VI receptor 
(Beljaars et al., 2000). 
In conclusion, due to the lack of antifibrotic drugs at present, the investigation of 
endocannabinoids and their promising functions in fibrogenesis will be an important issue in 
future work. 
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6 SUMMARY  
Liver fibrosis is the response to chronic hepatic injury and results from an excessive 
deposition of connective scar tissue. Liver cirrhosis, the end stage of fibrosis, leads to further 
severe complications like ascites and peritonitis resulting in a high mortality rate worldwide. 
Hepatic stellate cells (HSCs) are the main responsible cells for the increased synthesis of 
extracellular tissue. While cell death in hepatocytes, the parenchymal cells in the liver, plays 
a pivotal role in the activation of HSCs and deterioration of this disease, removal of activated 
HSCs preceded amelioration of fibrosis. 
In this thesis it was shown the first time, that the endocannabinoids virodhamine, noladin 
ether and N-arachidonoyl dopamine (NADA) specifically induce cell death in HSCs. Due to 
the selective expression of effective defense systems like antioxidants and the NADA 
degradation enzyme fatty acid amide hydrolase (FAAH), hepatocytes showed resistance to 
NADA-induced cell death. The rate limiting enzyme of NADA, tyrosine hydroxylase, was 
shown to be strongly expressed in hepatocytes in the healthy as well as the injured liver. 
Thus, NADA has potential as an antifibrotic endogenous agent. 
It was recently demonstrated that the endogenous cannabinoid 2-arachidonoyl glycerol (2-
AG) is strongly upregulated in the injured liver. The present study showed that the main 2-AG 
producing cells are liver sinusoidal endothelial cells (LSECs). They showed a strong 
expression of the 2-AG synthesising enzyme DAGLβ as well as of the degradation enzyme 
monoacylglycerol lipase (MGL). Elevated 2-AG levels during fibrogenesis are rather driven 
by decreased degradation than by upregulation of 2-AG production.  
It is known that 2-AG specifically induces cell death in HSCs but not in hepatocytes. To 
examine the different susceptibility of HSCs and hepatocytes to 2-AG-induced cell death, the 
role of an alternative metabolic pathway of 2-AG was investigated. In this pathway, 2-AG is 
converted to prostaglandin glycerol esters (PG-GEs) by the catalytic activity of 
cyclooxygenase-2 (COX-2). It could be shown, that COX-2 is highly expressed in HSCs but 
not in hepatocytes. Furthermore, HSCs are able to produce PGD2-GE after 2-AG exposure. 
PGD2-GE had cytotoxic effects on HSCs as well as on hepatocytes. Hepatocytes are 
resistant to 2-AG-induced cell death possibly due to the lack of COX-2 and the missing 
production of cytotoxic PGD2-GE. The results in this study represent an important step in the 
understanding of 2-AG-mediated pathways in liver injury and make it possible to specifically 
target components of this system to decrease hepatic fibrogenesis. 
In conclusion, the present study has provided new findings about the mechanism of 2-AG-
signalling in liver injury. Moreover, a possible functional role of NADA during liver injury was 
investigated. These results faciliate the use of components of the endocannabinoid system 
for antifibrotic, therapeutical purposes.                                                        
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